<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biomol Struct Dyn</journal-id><journal-id journal-id-type="iso-abbrev">J. Biomol. Struct. Dyn</journal-id><journal-title-group><journal-title>Journal of Biomolecular Structure &#x00026; Dynamics</journal-title></journal-title-group><issn pub-type="ppub">0739-1102</issn><issn pub-type="epub">1538-0254</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7441777</article-id><article-id pub-id-type="doi">10.1080/07391102.2020.1796810</article-id><article-id pub-id-type="publisher-id">1796810</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 <italic>via</italic> RNA&#x02010;dependent RNA polymerase (RdRp) inhibition: an <italic>in-silico</italic> analysis</article-title><alt-title alt-title-type="left-running-head">S. Singh et al.</alt-title><alt-title alt-title-type="right-running-head">Journal of Biomolecular Structure and Dynamics</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2341-9544</contrib-id><name><surname>Singh</surname><given-names>Satyam</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4341-8370</contrib-id><name><surname>Sk</surname><given-names>Md Fulbabu</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Sonawane</surname><given-names>Avinash</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8451-9739</contrib-id><name><surname>Kar</surname><given-names>Parimal</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3302-5875</contrib-id><name><surname>Sadhukhan</surname><given-names>Sushabhan</given-names></name><xref ref-type="aff" rid="AF0002">b</xref><xref ref-type="corresp" rid="AN0001"/></contrib><aff id="AF0001"><label>a</label><institution>Discipline of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore</institution>, <city>Indore</city>, <country>India</country>; &#x000a0;</aff><aff id="AF0002"><label>b</label><institution>Discipline of Chemistry, Indian Institute of Technology Palakkad</institution>, <city>Palakkad</city>, <country>India</country></aff></contrib-group><author-notes><fn id="AUFN2"><p>Supplemental data for this article can be accessed online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07391102.2020.1796810">https://doi.org/10.1080/07391102.2020.1796810</ext-link>.</p></fn><corresp id="AN0001"><bold>CONTACT</bold> Sushabhan Sadhukhan <email>sushabhan@iitpkd.ac.in</email><institution>Discipline of Chemistry, Indian Institute of Technology Palakkad</institution>,<state>Kerala</state><postal-code>678 557</postal-code>, <country>India</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>28</day><month>7</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2020</year></pub-date><fpage seq="1">1</fpage><lpage>16</lpage><permissions><copyright-statement>&#x000a9; 2020 Informa UK Limited, trading as Taylor &#x00026; Francis Group</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Informa UK Limited, trading as Taylor &#x00026; Francis Group</copyright-holder><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="TBSD_0_1796810.pdf"/><abstract><title>Abstract</title><p>The sudden outburst of Coronavirus disease (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) poses a massive threat to global public health. Currently, no therapeutic drug or vaccine exists to treat COVID-19. Due to the time taking process of new drug development, drug repurposing might be the only viable solution to tackle COVID-19. RNA&#x02010;dependent RNA polymerase (RdRp) catalyzes SARS-CoV-2 RNA replication and hence, is an obvious target for antiviral drug design. Interestingly, several plant-derived polyphenols effectively inhibit the RdRp of other RNA viruses. More importantly, polyphenols have been used as dietary supplementations for a long time and played beneficial roles in immune homeostasis. We were curious to study the binding of polyphenols with SARS-CoV-2 RdRp and assess their potential to treat COVID-19. Herein, we made a library of polyphenols that have shown substantial therapeutic effects against various diseases. They were successfully docked in the catalytic pocket of RdRp. The investigation reveals that EGCG, theaflavin (TF1), theaflavin-3&#x02019;-<italic>O</italic>-gallate (TF2a), theaflavin-3&#x02019;-gallate (TF2b), theaflavin 3,3'-digallate (TF3), hesperidin, quercetagetin, and myricetin strongly bind to the active site of RdRp. Further, a 150-ns molecular dynamic simulation revealed that EGCG, TF2a, TF2b, TF3 result in highly stable bound conformations with RdRp. The binding free energy components calculated by the MM-PBSA also confirm the stability of the complexes. We also performed a detailed analysis of ADME prediction, toxicity prediction, and target analysis for their druggability. Overall, our results suggest that EGCG, TF2a, TF2b, TF3 can inhibit RdRp and represent an effective therapy for COVID-19.</p><p>Communicated by Ramaswamy H. Sarma</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>SARS-CoV-2 and RNA&#x02010;dependent RNA polymerase (RdRp)</kwd><kwd>molecular docking</kwd><kwd>molecular dynamics</kwd><kwd>MM-PBSA</kwd><kwd>natural polyphenols</kwd></kwd-group><counts><fig-count count="8"/><table-count count="7"/><page-count count="16"/><word-count count="10625"/></counts></article-meta></front><body><sec id="S0001" disp-level="1"><label>1.</label><title>Introduction</title><p>An outbreak of Coronavirus disease (COVID-19) has caused a pandemic situation across the globe. Although the outburst was first observed at Wuhan city in China, at present more than 200 countries and territories around the world have witnessed the COVID-19 fatalities affecting all age groups. As of July 03, 2020, more than 11 million people have been affected by the disease, with a fatality of 5,25,410 across the globe as per the WHO report. Unfortunately, there is no clinically approved drug or vaccine for COVID-19 as of now. The disease is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a member of the Coronaviridae family of viruses and it belongs to the same family <italic>Betacoronaviruses,</italic> like Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (Chan et&#x000a0;al., <xref rid="CIT0011" ref-type="bibr">2015</xref>; Elfiky &#x00026; Azzam, <xref rid="CIT0021" ref-type="bibr">2020</xref>; Ibrahim et&#x000a0;al., <xref rid="CIT0029" ref-type="bibr">2020</xref>). The symptoms of SARS-CoV-2 infection include fever, dry cough, shortness of breath, runny nose, and sore throat (Wu et&#x000a0;al., <xref rid="CIT0072" ref-type="bibr">2020</xref>). SARS-CoV-2 is a positive-sense single-stranded RNA virus, and its genome is around 29.7&#x02009;kB long with twelve putative open reading frames (ORFs) that encode different viral structural and non-structural proteins. There are four structural proteins in SARS-CoV-2, namely spike (S), envelope (E), membrane (M), and nucleocapsid (N), and all of them can potentially serve as an antigen for neutralizing antibody preparation as potential therapeutics (Boopathi et&#x000a0;al., <xref rid="CIT0007" ref-type="bibr">2020</xref>).</p><p>Another potential drug target for SARS-CoV-2 is RNA&#x02010;dependent RNA polymerase (RdRp) (<xref ref-type="fig" rid="F0001">Figure 1</xref>), which is a key component of the replication machinery of the virus to make multiple copies of the RNA genome (Elfiky <xref rid="CIT0020" ref-type="bibr">2020c</xref>). RdRp in various coronaviruses are remarkably similar. For example, the RdRp of SARS-CoV exhibits &#x0223c;97% sequence similarity with that of SARS-CoV-2. More importantly, there is no human polymerase counterpart that resembles the sequence/structural homology with RdRp from coronaviruses, and hence, the development of RdRp inhibitors could be a potential therapeutic strategy without risk of crosstalk with human polymerases (Borgio et&#x000a0;al., <xref rid="CIT0008" ref-type="bibr">2020</xref>; Subissi et&#x000a0;al., <xref rid="CIT0065" ref-type="bibr">2014</xref>; Zhai et&#x000a0;al., <xref rid="CIT0077" ref-type="bibr">2005</xref>). Very recently, Yin et&#x000a0;al. reported the crystal structure RdRp of SARS-CoV-2 complexed with an antiviral drug, Remdesivir highlighting how the template-primer RNA is recognized by the polymerase enzyme and the chain elongation is inhibited by Remdesivir providing a basis for developing a wide range of effective inhibitors to overcome from SARS-CoV-2 infection (Yin et&#x000a0;al., <xref rid="CIT0075" ref-type="bibr">2020</xref>). RdRp has been found to be an effective drug target for several other RNA viruses, spanning from the hepatitis C virus, zika virus to coronaviruses (Elfiky, <xref rid="CIT0016" ref-type="bibr">2017</xref>, <xref rid="CIT0017" ref-type="bibr">2019</xref>; Ganesan &#x00026; Barakat, <xref rid="CIT0024" ref-type="bibr">2017</xref>). The active site of RdRp is highly conserved, and the catalytic domains contain two consecutive aspartate residues in a beta-turn joining &#x003b2;15 and &#x003b2;16 (Elfiky <xref rid="CIT0020" ref-type="bibr">2020c</xref>). The general structure of RdRp consists of 7 motifs (A to G) among them inner channel of catalytic sites represented by motif A to C, and they play a crucial role during the nucleotide addition cycle (Jia &#x00026; Gong, <xref rid="CIT0032" ref-type="bibr">2019</xref>; Wu &#x00026; Gong, <xref rid="CIT0073" ref-type="bibr">2018</xref>).</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>The 3-dimensional crystal structure of RNA&#x02010;dependent RNA polymerase (RdRp).</p></caption><graphic content-type="color" xlink:href="TBSD_A_1796810_F0001_C"/></fig><p>Epidemiological studies repetitively suggested that consumption of bioactive compounds (<italic>e.g.</italic> vitamins, phytochemicals, polyphenols, flavonoids, flavonols, and carotenoids etc.) has beneficial activity on human health and could minimize the risk of various diseases starting from cancers to different viral infections (Khan et&#x000a0;al., <xref rid="CIT0043" ref-type="bibr">2020</xref>; Szajdek &#x00026; Borowska, <xref rid="CIT0066" ref-type="bibr">2008</xref>). Traditional natural compounds have been consumed since ancient times as they exhibit less toxicity, low-cost availability, minimum side-effects and are rich in therapeutic resources. Some of the previous findings also suggest that naturally occurring compounds possess a wide range of antiviral properties against RNA viruses, including polio-virus type 1, parainfluenza virus type 3, and respiratory syncytial virus by inhibiting their replication (Lin et&#x000a0;al., <xref rid="CIT0049" ref-type="bibr">2014</xref>). In that context, Ahmed-Belkacem et&#x000a0;al. have screened more than forty potent natural flavonoids for their polymerase inhibition activity using HCV-NS5 strain and among the different flavonoids, quercetagetin showed strong HCV replication inhibitory activity <italic>in&#x000a0;vitro</italic> (Ahmed-Belkacem et&#x000a0;al., <xref rid="CIT0003" ref-type="bibr">2014</xref>). Previously, song et&#x000a0;al. reported that green tea catechins, by disrupting the membrane of the influenza virus, inhibited neuraminidase in the crude system (Song et&#x000a0;al., <xref rid="CIT0064" ref-type="bibr">2005</xref>). On a separate report, Takashi et&#x000a0;al. reported that EGCG, a green tea polyphenol can inhibit the endonuclease activity of influenza A virus RNA polymerase. EGCG is also reported to interfere with viral replication <italic>via</italic> modulating the cellular redox environment (Ho et&#x000a0;al., <xref rid="CIT0028" ref-type="bibr">2009</xref>; Kuzuhara et&#x000a0;al., <xref rid="CIT0047" ref-type="bibr">2009</xref>). Therefore, the existing scientific evidence strongly suggests that natural flavonoids/polyphenol can act against SARS-CoV-2 (Aanouz et&#x000a0;al., <xref rid="CIT0001" ref-type="bibr">2020</xref>; Elfiky <xref rid="CIT0019" ref-type="bibr">2020b</xref>; Elmezayen et&#x000a0;al., <xref rid="CIT0022" ref-type="bibr">2020</xref>; Enmozhi et&#x000a0;al., <xref rid="CIT0023" ref-type="bibr">2020</xref>). Because of the time-consuming process of new synthetic/semi-synthetic drug development, drug repurposing of phytomolecules is an ideal alternative in this urgent situation as the latter process is economical and scalable in a very short period of time (Adeoye et&#x000a0;al., <xref rid="CIT0002" ref-type="bibr">2020</xref>; Islam et&#x000a0;al., <xref rid="CIT0030" ref-type="bibr">2020</xref>; Muralidharan et&#x000a0;al., <xref rid="CIT0054" ref-type="bibr">2020</xref>; Sinha et&#x000a0;al., <xref rid="CIT0061" ref-type="bibr">2020</xref>). Hence, a comprehensive understanding of their binding to SARS-CoV-2 RdRp can yield interesting findings that can further be capitalized to develop COVID-19 drugs. Nevertheless, the apparent lack of cytotoxicity of polyphenols at even significantly high concentrations makes them potential antiviral drug candidates. In the present study, we selected a hundred natural polyphenols to assess their potential to act as SARS-CoV-2 RdRp inhibitors. The selected library was then explored to evaluate the binding affinity of individual polyphenols towards RdRp of the SARS-CoV-2 by molecular docking using AutoDock vina. Among the selected polyphenols, theaflavin (TF1), theaflavin-3&#x02032;-O-gallate (TF2a), theaflavin-3&#x02032;-gallate (TF2b), theaflavin 3,3&#x02032;-digallate (TF3), hesperidin, EGCG, myricetin, and quercetagetin were found to be docked in the active site of RdRp of the SARS-CoV-2 with a highly favourable affinity for the binding pocket. Further to get a better understanding of the dynamics of the complexes, we performed a 150-nanoseconds molecular dynamic simulation with those eight polyphenols. The binding free energy components were calculated by the MM-PBSA. Remdesivir (Hendaus, <xref rid="CIT0027" ref-type="bibr">2020</xref>) and GTP (a physiological nucleotide) were taken as positive controls to validate our results.</p></sec><sec id="S0002" disp-level="1"><label>2.</label><title>Materials and methods</title><sec id="S0002-S2001" disp-level="2"><label>2.1.</label><title>Molecular docking studies</title><sec id="S0002-S2001-S3001" disp-level="3"><label>2.1.1.</label><title>Protein preparations</title><p>The crystal structure of SARS-CoV-2 RdRp (PDB ID: 6M71) (Yan et&#x000a0;al., <xref rid="CIT0074" ref-type="bibr">2020</xref>) was retrieved from the protein databank (<ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org">www.rcsb.org</ext-link>) (Berman et&#x000a0;al., <xref rid="CIT0005" ref-type="bibr">2000</xref>). The crystal structure was prepared individually by adding hydrogen atoms and computing the Gasteiger charge using the AutoDock v4.2 program (Morris et&#x000a0;al., <xref rid="CIT0053" ref-type="bibr">2009</xref>). Subsequently, the file was saved as .pdbqt format in preparation for molecular docking. Schematic representation of the work-flow for selecting potential natural polyphenolic inhibitors for the SARS-CoV-2 RdRp is shown in <xref ref-type="fig" rid="F0002">Figure 2</xref>.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Flow chart of the methodology for shortlisting the best natural polyphenolic inhibitor of the SARS-CoV-2 RdRp.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1796810_F0002_C"/></fig></sec><sec id="S0002-S2001-S3002" disp-level="3"><label>2.1.2.</label><title>Ligand preparations</title><p>The SDF structures of GTP, remdesivir, and selected hundred polyphenols (see <xref rid="t0001" ref-type="table">Table S1</xref> in <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07391102.2020.1796810">Supplementary Information</ext-link>) were retrieved from the PubChem database (<ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/">https://pubchem.ncbi.nlm.nih.gov/</ext-link>) (Kim et&#x000a0;al., <xref rid="CIT0044" ref-type="bibr">2019</xref>). The compounds were converted into PDB format, and conformational energies of all the compounds were minimized by using UCSF Chimera (Pettersen et&#x000a0;al., <xref rid="CIT0055" ref-type="bibr">2004</xref>).</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Binding energy (kcal/mol) of the natural polyphenols along with the control compounds (GTP and remdesivir) against RdRp of the SARS-CoV-2 (PDB ID: 6M71) by molecular docking study.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">S. No.</th><th align="center">Compound Name</th><th align="center">Binding energy (kcal/mol)</th><th align="center">S. No.</th><th align="center">Compound Name</th><th align="center">Binding energy (kcal/mol)</th></tr></thead><tbody valign="top"><tr><td align="left">1</td><td align="left"><bold>TF3</bold></td><td align="char" char="."><bold>&#x02212;9.9</bold></td><td align="char" char=".">52</td><td align="center">Cyanidin</td><td align="char" char=".">&#x02212;6.3</td></tr><tr><td align="left">2</td><td align="left"><bold>TF2b</bold></td><td align="char" char="."><bold>&#x02212;9.6</bold></td><td align="char" char=".">53</td><td align="center">Daidzein</td><td align="char" char=".">&#x02212;6.3</td></tr><tr><td align="left">3</td><td align="left"><bold>TF1</bold></td><td align="char" char="."><bold>&#x02212;9.6</bold></td><td align="char" char=".">54</td><td align="center">Glycitein</td><td align="char" char=".">&#x02212;6.3</td></tr><tr><td align="left">4</td><td align="left"><bold>TF2a</bold></td><td align="char" char="."><bold>&#x02212;9.3</bold></td><td align="char" char=".">55</td><td align="center">Wogonin</td><td align="char" char=".">&#x02212;6.3</td></tr><tr><td align="left">5</td><td align="left"><bold>Hesperidin</bold></td><td align="char" char="."><bold>&#x02212;8.8</bold></td><td align="char" char=".">56</td><td align="center">Phloretin</td><td align="char" char=".">&#x02212;6.3</td></tr><tr><td align="left">6</td><td align="left"><bold>EGCG</bold></td><td align="char" char="."><bold>&#x02212;7.3</bold></td><td align="char" char=".">57</td><td align="center">Catechin</td><td align="char" char=".">&#x02212;6.2</td></tr><tr><td align="left">7</td><td align="left"><bold>Myricetin</bold></td><td align="char" char="."><bold>&#x02212;7.2</bold></td><td align="char" char=".">58</td><td align="center">Urolithin B</td><td align="char" char=".">&#x02212;6.2</td></tr><tr><td align="left">8</td><td align="left"><bold>Quercetagetin</bold></td><td align="char" char="."><bold>&#x02212;7.0</bold></td><td align="char" char=".">59</td><td align="center">Angolensin</td><td align="char" char=".">&#x02212;6.2</td></tr><tr><td align="left">9</td><td align="left">Quercetin</td><td align="char" char=".">&#x02212;6.9</td><td align="char" char=".">60</td><td align="center">Pinosylvin</td><td align="char" char=".">&#x02212;6.2</td></tr><tr><td align="left">10</td><td align="left">Curcumin</td><td align="char" char=".">&#x02212;6.9</td><td align="char" char=".">61</td><td align="center">Formononetin</td><td align="char" char=".">&#x02212;6.2</td></tr><tr><td align="left">11</td><td align="left">Dihydrorobinetin</td><td align="char" char=".">&#x02212;6.8</td><td align="char" char=".">62</td><td align="center">Liquiritigenin</td><td align="char" char=".">&#x02212;6.2</td></tr><tr><td align="left">12</td><td align="left">Peonidin</td><td align="char" char=".">&#x02212;6.8</td><td align="char" char=".">63</td><td align="center">Prunetin</td><td align="char" char=".">&#x02212;6.2</td></tr><tr><td align="left">13</td><td align="left">Fisetin</td><td align="char" char=".">&#x02212;6.8</td><td align="char" char=".">64</td><td align="center">Alpinetin</td><td align="char" char=".">&#x02212;6.2</td></tr><tr><td align="left">14</td><td align="left">Robinetin</td><td align="char" char=".">&#x02212;6.7</td><td align="char" char=".">65</td><td align="center">Biochanin A</td><td align="char" char=".">&#x02212;6.2</td></tr><tr><td align="left">15</td><td align="left">5-Deoxygalangin</td><td align="char" char=".">&#x02212;6.7</td><td align="char" char=".">66</td><td align="center">Rhapontigenin</td><td align="char" char=".">&#x02212;6.1</td></tr><tr><td align="left">16</td><td align="left">Kaempferol</td><td align="char" char=".">&#x02212;6.7</td><td align="char" char=".">67</td><td align="center">Genistein</td><td align="char" char=".">&#x02212;6.1</td></tr><tr><td align="left">17</td><td align="left">Scutellarein</td><td align="char" char=".">&#x02212;6.7</td><td align="char" char=".">68</td><td align="center">Chrysin</td><td align="char" char=".">&#x02212;6.1</td></tr><tr><td align="left">18</td><td align="left"><italic toggle="yes">(-)</italic>-Epicatechin</td><td align="char" char=".">&#x02212;6.7</td><td align="char" char=".">69</td><td align="center">6-Hydroxyflavone</td><td align="char" char=".">&#x02212;6.1</td></tr><tr><td align="left">19</td><td align="left">Purpurin</td><td align="char" char=".">&#x02212;6.7</td><td align="char" char=".">70</td><td align="center">Equol</td><td align="char" char=".">&#x02212;6.1</td></tr><tr><td align="left">20</td><td align="left">Isorhamnetin</td><td align="char" char=".">&#x02212;6.7</td><td align="char" char=".">71</td><td align="center">Piceatannol</td><td align="char" char=".">&#x02212;6.1</td></tr><tr><td align="left">21</td><td align="left">Tricetin</td><td align="char" char=".">&#x02212;6.6</td><td align="char" char=".">72</td><td align="center">Isorhapontigenin</td><td align="char" char=".">&#x02212;6.0</td></tr><tr><td align="left">22</td><td align="left">Gossypetin</td><td align="char" char=".">&#x02212;6.6</td><td align="char" char=".">73</td><td align="center">Resveratrol</td><td align="char" char=".">&#x02212;5.8</td></tr><tr><td align="left">23</td><td align="left">Norathyriol</td><td align="char" char=".">&#x02212;6.6</td><td align="char" char=".">74</td><td align="center">Danshensu</td><td align="char" char=".">&#x02212;5.7</td></tr><tr><td align="left">24</td><td align="left">Coumestrol</td><td align="char" char=".">&#x02212;6.6</td><td align="char" char=".">75</td><td align="center">Eugenin</td><td align="char" char=".">&#x02212;5.6</td></tr><tr><td align="left">25</td><td align="left">Isosakuranetin</td><td align="char" char=".">&#x02212;6.6</td><td align="char" char=".">76</td><td align="center">Sinapic acid</td><td align="char" char=".">&#x02212;5.5</td></tr><tr><td align="left">26</td><td align="left">Pectolinarigenin</td><td align="char" char=".">&#x02212;6.6</td><td align="char" char=".">77</td><td align="center">Pterostilbene</td><td align="char" char=".">&#x02212;5.5</td></tr><tr><td align="left">27</td><td align="left">Tangeritin</td><td align="char" char=".">&#x02212;6.6</td><td align="char" char=".">78</td><td align="center">Ferulic acid</td><td align="char" char=".">&#x02212;5.4</td></tr><tr><td align="left">28</td><td align="left">Nobiletin</td><td align="char" char=".">&#x02212;6.6</td><td align="char" char=".">79</td><td align="center">Caffeic acid</td><td align="char" char=".">&#x02212;5.4</td></tr><tr><td align="left">29</td><td align="left">Pratensein</td><td align="char" char=".">&#x02212;6.6</td><td align="char" char=".">80</td><td align="center">Isoferulic acid</td><td align="char" char=".">&#x02212;5.4</td></tr><tr><td align="left">30</td><td align="left">Hispidulin</td><td align="char" char=".">&#x02212;6.6</td><td align="char" char=".">81</td><td align="center">Dihydrocaffeic acid</td><td align="char" char=".">&#x02212;5.4</td></tr><tr><td align="left">31</td><td align="left">Baicalein</td><td align="char" char=".">&#x02212;6.5</td><td align="char" char=".">82</td><td align="center">Gentisic acid</td><td align="char" char=".">&#x02212;5.3</td></tr><tr><td align="left">32</td><td align="left">Apigenin</td><td align="char" char=".">&#x02212;6.5</td><td align="char" char=".">83</td><td align="center">Pyrogallol</td><td align="char" char=".">&#x02212;5.3</td></tr><tr><td align="left">33</td><td align="left">Morin</td><td align="char" char=".">&#x02212;6.5</td><td align="char" char=".">84</td><td align="center">4-Hydroxycinnamic acid</td><td align="char" char=".">&#x02212;5.2</td></tr><tr><td align="left">34</td><td align="left">Urolithin A</td><td align="char" char=".">&#x02212;6.5</td><td align="char" char=".">85</td><td align="center">Resacetophenone</td><td align="char" char=".">&#x02212;5.2</td></tr><tr><td align="left">35</td><td align="left">Acacetin</td><td align="char" char=".">&#x02212;6.5</td><td align="char" char=".">86</td><td align="center">Salicyclic acid</td><td align="char" char=".">&#x02212;5.1</td></tr><tr><td align="left">36</td><td align="left">Pelargonidin</td><td align="char" char=".">&#x02212;6.5</td><td align="char" char=".">87</td><td align="center">Syringic acid</td><td align="char" char=".">&#x02212;5.1</td></tr><tr><td align="left">37</td><td align="left">Irilone</td><td align="char" char=".">&#x02212;6.5</td><td align="char" char=".">88</td><td align="center">2-Hydroxybenzoic acid</td><td align="char" char=".">&#x02212;5.1</td></tr><tr><td align="left">38</td><td align="left">Naringenin</td><td align="char" char=".">&#x02212;6.5</td><td align="char" char=".">89</td><td align="center">Gallic acid</td><td align="char" char=".">&#x02212;5.0</td></tr><tr><td align="left">39</td><td align="left">Pinocembrin</td><td align="char" char=".">&#x02212;6.5</td><td align="char" char=".">90</td><td align="center">3-Hydroxybenzoic acid</td><td align="char" char=".">&#x02212;5.0</td></tr><tr><td align="left">40</td><td align="left">Kaempferide</td><td align="char" char=".">&#x02212;6.5</td><td align="char" char=".">91</td><td align="center">4-Hydroxybenzoic acid</td><td align="char" char=".">&#x02212;5.0</td></tr><tr><td align="left">41</td><td align="left">Malvidin</td><td align="char" char=".">&#x02212;6.5</td><td align="char" char=".">92</td><td align="center">Vanillin</td><td align="char" char=".">&#x02212;5.0</td></tr><tr><td align="left">42</td><td align="left">Luteolin</td><td align="char" char=".">&#x02212;6.4</td><td align="char" char=".">93</td><td align="center"><italic toggle="yes">p</italic>-Coumeric acid</td><td align="char" char=".">&#x02212;4.9</td></tr><tr><td align="left">43</td><td align="left">Dalbergin</td><td align="char" char=".">&#x02212;6.4</td><td align="char" char=".">94</td><td align="center">Vanillic acid</td><td align="char" char=".">&#x02212;4.8</td></tr><tr><td align="left">44</td><td align="left">Butein</td><td align="char" char=".">&#x02212;6.4</td><td align="char" char=".">95</td><td align="center">Paeonol</td><td align="char" char=".">&#x02212;4.8</td></tr><tr><td align="left">45</td><td align="left">Biochanin A (1-)</td><td align="char" char=".">&#x02212;6.4</td><td align="char" char=".">96</td><td align="center">Cinnamic acid</td><td align="char" char=".">&#x02212;4.7</td></tr><tr><td align="left">46</td><td align="left">Fustin</td><td align="char" char=".">&#x02212;6.4</td><td align="char" char=".">97</td><td align="center">Protocatechuic acid</td><td align="char" char=".">&#x02212;4.6</td></tr><tr><td align="left">47</td><td align="left">5-Hydroxyflavone</td><td align="char" char=".">&#x02212;6.4</td><td align="char" char=".">98</td><td align="center">4-Ethylphenol</td><td align="char" char=".">&#x02212;4.5</td></tr><tr><td align="left">48</td><td align="left">Pinostrobin</td><td align="char" char=".">&#x02212;6.4</td><td align="char" char=".">99</td><td align="center">Catechol</td><td align="char" char=".">&#x02212;4.5</td></tr><tr><td align="left">49</td><td align="left">Pinobanksin</td><td align="char" char=".">&#x02212;6.4</td><td align="char" char=".">100</td><td align="center">Tyrosol</td><td align="char" char=".">&#x02212;4.5</td></tr><tr><td align="left">50</td><td align="left">Datiscetin</td><td align="char" char=".">&#x02212;6.3</td><td align="char" char=".">101</td><td align="center"><bold>GTP</bold></td><td align="char" char="."><bold>&#x02212;7.9</bold></td></tr><tr><td align="left">51</td><td align="left">Galangin</td><td align="char" char=".">&#x02212;6.3</td><td align="char" char=".">102</td><td align="center"><bold>Remdesivir</bold></td><td align="char" char="."><bold>&#x02212;7.7</bold></td></tr></tbody></table></table-wrap></sec><sec id="S0002-S2001-S3003" disp-level="3"><label>2.1.3.</label><title>Docking studies using AutoDock Vina</title><p>The energy-minimized structure of all the natural polyphenols, remdesivir, and GTP were docked with the receptor (RdRp of SARS-CoV-2) using AutoDock Vina 1.1.2 (Trott &#x00026; Olson, <xref rid="CIT0067" ref-type="bibr">2010</xref>). The ligand files were further saved in PDBQT file format, a modified PDB format containing atomic charges, atom type definitions for ligands, and topological information (rotatable bonds). A grid box (30 &#x000c5;&#x02009;&#x000d7;&#x02009;30&#x02009;&#x000c5;&#x02009;&#x000d7;&#x02009;30&#x02009;&#x000c5;) centered at (121, 120, 125) &#x000c5; for the SARS-CoV-2 RdRp, was used in the docking experiments. After the receptor-ligand preparation, docking runs were started from the command prompt. The lowest binding energy and best-docked conformation were considered as the ligand molecule with maximum binding affinity.</p></sec><sec id="S0002-S2001-S3004" disp-level="3"><label>2.1.4.</label><title>Protein-ligand interactions</title><p>LigPlot<sup>+</sup> was used to investigate protein-ligand interactions for a given .pdb file containing the docked conformation and also the final simulated conformation (Wallace et&#x000a0;al., <xref rid="CIT0068" ref-type="bibr">1995</xref>). The LigPlot<sup>+</sup> program self-generated schematic 2D representations of protein-ligand interaction. The output file represents the intermolecular interactions and their strengths, including hydrogen bonds, hydrophobic contacts, and atom accessibilities. H-bonds are shown in green dotted lines, whereas residues involved in hydrophobic interaction are represented in the red semicircle.</p></sec></sec><sec id="S0002-S2002" disp-level="2"><label>2.2.</label><title>Molecular dynamics simulations</title><p>All-atom molecular dynamics (MD) simulations were performed on the best eight selected plant-derived natural polyphenols obtained from the molecular docking study along with remdesivir, a well-known RdRp inhibitor, for studying thermodynamic stability of the docked structure. The <italic>pmemd.cuda</italic> module in AMBER18 (Case et&#x000a0;al. <xref rid="CIT0010" ref-type="bibr">2018</xref>) was used for conducting MD simulations, and all simulations were performed utilizing the graphics card, RTX 2080Ti. We adopted the same protocol that was used in our earlier studies (Jonniya et&#x000a0;al., <xref rid="CIT0034" ref-type="bibr">2019</xref>; Sk, Roy, Jonniya, et&#x000a0;al., <xref rid="CIT0062" ref-type="bibr">2020</xref>; Sk, Roy, &#x00026; Kar, <xref rid="CIT0063" ref-type="bibr">2020</xref>). The receptor and small molecules were described by the Amber ff14SB (Maier et&#x000a0;al., <xref rid="CIT0051" ref-type="bibr">2015</xref>) and GAFF2 (Wang et&#x000a0;al., <xref rid="CIT0071" ref-type="bibr">2004</xref>) force field, respectively. Ligands were assigned the AM1-BCC (Jakalian et&#x000a0;al., <xref rid="CIT0031" ref-type="bibr">2002</xref>) atomic charges calculated using the <italic>antechamber</italic> (Wang et&#x000a0;al., <xref rid="CIT0069" ref-type="bibr">2001</xref>) module. The complexes were then solvated using an explicit TIP3P (Price &#x00026; Brooks III, <xref rid="CIT0057" ref-type="bibr">2004</xref>) water model, and nearly 38124 water molecules were needed to solvate each system. Subsequently, all solvated systems were neutralized by adding an appropriate number of Na<sup>+</sup> ion. All bond lengths, including hydrogen atoms, were constrained by the SHAKE algorithm (Kr&#x000e4;utler et&#x000a0;al., <xref rid="CIT0046" ref-type="bibr">2001</xref>). This allows the usage of a 2 fs time-step. The non-bonded cut-off was set to 8&#x02009;&#x000c5; and the long range electrostatic interactions were evaluated using the particle-mesh Ewald (PME) (Darden et&#x000a0;al., <xref rid="CIT0015" ref-type="bibr">1993</xref>) method. The temperature was kept at 300&#x02009;K using the Langevin thermostat (Loncharich et&#x000a0;al., <xref rid="CIT0050" ref-type="bibr">1992</xref>) with a collision frequency of 2&#x02009;ps<sup>&#x02212;1</sup>. The system pressure was controlled by Berendsen&#x02019;s Barostat (Berendsen et&#x000a0;al., <xref rid="CIT0004" ref-type="bibr">1984</xref>) and fixed at 1.0&#x02009;bar. We used a time-step of 2.0 fs for all simulations.</p><p>Briefly, we used two stages of minimization. Firstly, each complex was optimized by 500 steps of steepest descent followed by another 500 steps of conjugate gradient minimization, keeping all atoms of the complex restrained to their initial coordinate with a weak harmonic potential (force constant 2.0&#x02009;kcal mol<sup>&#x02212;1&#x02009;</sup>&#x000c5;<sup>&#x02212;2</sup>). The second stage of minimization was carried out without any restraints by performing 100 steps of steepest descent, followed by another 900 steps of conjugate gradient minimization to remove any residual steric clashes. Subsequently, all systems were gradually heated from 0&#x02009;K to 300&#x02009;K at the NVT ensemble with a force constant of 2.0&#x02009;kcal mol<sup>&#x02212;1</sup>&#x000c5;<sup>&#x02212;2</sup> acting on all solute atoms. Next, 1.0&#x02009;ns equilibration MD phase was carried out without any restraint. Finally, we performed 150&#x02009;ns production simulations for all four systems at the NPT ensemble. Overall, we accumulated 15000 conformations for each simulation, and we used 500 snapshots from the last 50&#x02009;ns trajectories for binding affinity estimation using the MM-PBSA scheme. The trajectory analysis was done by the AmberTools19 CPPTRAJ (Roe &#x00026; Cheatham III, <xref rid="CIT0059" ref-type="bibr">2013</xref>) module of Amber18.</p></sec><sec id="S0002-S2003" disp-level="2"><label>2.3.</label><title>Molecular mechanics Poisson-Boltzmann surface area calculations</title><p>The binding affinity of EGCG, TF1, TF3, TF2b, TF2a, hesperidin, myricetin, quercetagetin, and remdesivir against the SARS-CoV-2 RdRp, were calculated by the molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) methodology (Jonniya &#x00026; Kar, <xref rid="CIT0033" ref-type="bibr">2020</xref>; Kar, Seel, et&#x000a0;al., <xref rid="CIT0041" ref-type="bibr">2007</xref>; Kar, Wei, et&#x000a0;al., <xref rid="CIT0042" ref-type="bibr">2007</xref>; Kar et&#x000a0;al., <xref rid="CIT0039" ref-type="bibr">2011</xref>; <xref rid="CIT0040" ref-type="bibr">2013</xref>; Kar &#x00026; Knecht, <xref rid="CIT0035" ref-type="bibr">2012a</xref>, <xref rid="CIT0036" ref-type="bibr">2012b</xref>, <xref rid="CIT0037" ref-type="bibr">2012c</xref>, <xref rid="CIT0038" ref-type="bibr">2012d</xref>; Kollman et&#x000a0;al., <xref rid="CIT0045" ref-type="bibr">2000</xref>; Roy et&#x000a0;al., <xref rid="CIT0060" ref-type="bibr">2020</xref>; Wang et&#x000a0;al., <xref rid="CIT0070" ref-type="bibr">2006</xref>). The MM-PBSA scheme can briefly be described as follows:
<disp-formula id="M0001"><label>(1)</label><alternatives><graphic xlink:href="TBSD_A_1796810_M0001.jpg" position="float" orientation="portrait"/><mml:math id="d1e1220"><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">bind</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>H</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>T</mml:mi><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>S</mml:mi><mml:mo>&#x02248;</mml:mo><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">MM</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">solv</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:mi>T</mml:mi><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>S</mml:mi></mml:math></alternatives></disp-formula>
<disp-formula id="M0002"><label>(2)</label><alternatives><graphic xlink:href="TBSD_A_1796810_M0002.jpg" position="float" orientation="portrait"/><mml:math id="d1e1267"><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">MM</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">internal</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">elec</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">vdW</mml:mi></mml:mrow></mml:msub></mml:math></alternatives></disp-formula>
<disp-formula id="M0003"><label>(3)</label><alternatives><graphic xlink:href="TBSD_A_1796810_M0003.jpg" position="float" orientation="portrait"/><mml:math id="d1e1308"><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">solv</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">pol</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">np</mml:mi></mml:mrow></mml:msub></mml:math></alternatives></disp-formula>
where <inline-formula id="ilm0001"><alternatives><inline-graphic xlink:href="TBSD_A_1796810_ILM0001.jpg"/><mml:math id="d1e1339"><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">MM</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:math></alternatives></inline-formula>
<inline-formula id="ilm0002"><alternatives><inline-graphic xlink:href="TBSD_A_1796810_ILM0002.jpg"/><mml:math id="d1e1353"><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">solv</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:math></alternatives></inline-formula>
<inline-formula id="ilm0003"><alternatives><inline-graphic xlink:href="TBSD_A_1796810_ILM0003.jpg"/><mml:math id="d1e1368"><mml:mi>T</mml:mi><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>S</mml:mi></mml:math></alternatives></inline-formula> are the changes in molecular mechanical energy, solvation free energy, and conformational entropy, respectively. Further, molecular mechanical energy is composed of <inline-formula id="ilm0004"><alternatives><inline-graphic xlink:href="TBSD_A_1796810_ILM0004.jpg"/><mml:math id="d1e1377"><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">internal</mml:mi></mml:mrow></mml:msub><mml:mi mathvariant="normal">&#x000a0;</mml:mi></mml:math></alternatives></inline-formula>(bond, dihedral, and angle), <inline-formula id="ilm0005"><alternatives><inline-graphic xlink:href="TBSD_A_1796810_ILM0005.jpg"/><mml:math id="d1e1392"><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">elec</mml:mi></mml:mrow></mml:msub></mml:math></alternatives></inline-formula> (electrostatic) and <inline-formula id="ilm0006"><alternatives><inline-graphic xlink:href="TBSD_A_1796810_ILM0006.jpg"/><mml:math id="d1e1405"><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">vdW</mml:mi></mml:mrow></mml:msub></mml:math></alternatives></inline-formula> (van der Waals) and the change in desolvation free energy is composed of polar solvation (<inline-formula id="ilm0007"><alternatives><inline-graphic xlink:href="TBSD_A_1796810_ILM0007.jpg"/><mml:math id="d1e1418"><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">pol</mml:mi></mml:mrow></mml:msub></mml:math></alternatives></inline-formula>) and non-polar solvation free energy (<inline-formula id="ilm0008"><alternatives><inline-graphic xlink:href="TBSD_A_1796810_ILM0008.jpg"/><mml:math id="d1e1431"><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">np</mml:mi></mml:mrow></mml:msub></mml:math></alternatives></inline-formula>). The polar solvation free energy, <inline-formula id="ilm0009"><alternatives><inline-graphic xlink:href="TBSD_A_1796810_ILM0009.jpg"/><mml:math id="d1e1445"><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">pol</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:math></alternatives></inline-formula> was calculated by the <italic>pbsa</italic> module of AMBER18. Due to the high computational cost, we neglect the configurational entropy calculations. Further, to understand the polyphenol-protein interaction more closely, the interaction energy was decomposed into the contributions from each residue of the protein by using the molecular mechanics generalized Born surface area (MM-GBSA) scheme (Gohlke et&#x000a0;al., <xref rid="CIT0026" ref-type="bibr">2003</xref>).</p></sec><sec id="S0002-S2004" disp-level="2"><label>2.4.</label><title>ADMET studies</title><p>The <italic>in-silico</italic> pharmacological studies of EGCG, TF2a, TF2b, TF3, and remdesivir were predicted based on their ADMET profile. The ADMET studies (absorption, distribution, metabolism, elimination, and toxicity) were predicted using the pkCSM tool (<ext-link ext-link-type="uri" xlink:href="http://biosig.unimelb.edu.au/pkcsm/prediction">http://biosig.unimelb.edu.au/pkcsm/prediction</ext-link>) (Pires et&#x000a0;al., <xref rid="CIT0056" ref-type="bibr">2015</xref>). The canonical SMILE molecular structures of the above-mentioned compounds were retrieved from the PubChem database (<ext-link ext-link-type="uri" xlink:href="http://www.pubchem.ncbi.nlm.nih.gov">www.pubchem.ncbi.nlm.nih.gov</ext-link>).</p></sec><sec id="S0002-S2005" disp-level="2"><label>2.5.</label><title>Molecular target prediction</title><p>Natural compounds interact with a large number of proteins, enzymes, lipids. This interaction plays a crucial role in elucidating the molecular mechanism of the small molecules. So, it is important to identify the molecular targets for new molecules (Gfeller et&#x000a0;al., <xref rid="CIT0025" ref-type="bibr">2014</xref>). Swiss Target Prediction website (<ext-link ext-link-type="uri" xlink:href="http://www.swisstargetprediction.ch/index.php">http://www.swisstargetprediction.ch/index.php</ext-link>) was logged on, and canonical SMILE molecular structures of remdesivir, EGCG, TF2a, TF2b, and TF3 were entered in the search bar option, and results were analyzed.</p></sec></sec><sec id="S0003" disp-level="1"><label>3.</label><title>Results and discussion</title><sec id="S0003-S2001" disp-level="2"><label>3.1.</label><title>Molecular docking analysis</title><sec id="S0003-S2001-S3001" disp-level="3"><label>3.1.1.</label><title>The binding mode analysis and predicted binding affinity calculations of natural polyphenols against the SARS-CoV-2 RdRp</title><p>Herein, we investigated our natural polyphenol library against RdRp of the SARS-CoV-2 (PDB ID: 6M71) by molecular docking. The best conformation of the natural polyphenols was docked against the SARS-CoV-2 RdRp, and resulting binding energies are listed in <xref rid="t0001" ref-type="table">Table 1</xref>.</p><p>Polyphenols exhibiting binding energy of &#x02212;7.0&#x02009;kcal/mol or lower (eight polyphenols) against RdRp of the SARS-CoV-2 are listed in <xref rid="t0002" ref-type="table">Table 2</xref> along with the ligand-amino acid interactions. Control compounds, GTP and remdesivir, exhibited the binding energy of &#x02212;7.9 and &#x02212;7.7&#x02009;kcal/mol, respectively, against the SARS-CoV-2 RdRp. Eight polyphenols displayed significantly higher binding affinity among the selected hundred natural polyphenols docked against the SARS-CoV-2 RdRp, with binding energies of TF3, TF2b, TF1, TF2a, hesperidin, EGCG, myricetin and quercetagetin as &#x02212;9.9, &#x02212;9.6, &#x02212;9.6, &#x02212;9.3, &#x02212;8.8, &#x02212;7.3, &#x02212;7.2 and &#x02212;7.0&#x02009;kcal/mol, respectively (highlighted in <xref rid="t0001" ref-type="table">Table 1</xref>). Further, 2D LigPlot<sup>+</sup> representation of RdRp and the above-mentioned eight polyphenols reveal the stable network of molecular interactions (see <xref rid="t0002" ref-type="table">Table 2</xref> and <xref ref-type="fig" rid="F0001">Figure S1</xref> in the <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07391102.2020.1796810">Supplementary Information</ext-link>).</p><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Ligand-amino acid interactions of top eight scoring natural polyphenols against the SARS-CoV-2 RdRp.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">S. No.</th><th align="center">Compound name</th><th align="center">Binding energy (kcal/mol)</th><th align="center">No. of non-covalent interactions</th><th align="center">Involved amino acids</th></tr></thead><tbody valign="top"><tr><td align="left">1</td><td align="center">TF3</td><td align="char" char=".">&#x02212;9.9</td><td align="char" char=".">17</td><td align="left">W617, K551, S549, D623, R836, S814, E811, F812, C813, D761, D618, S759, Y619, C622, R553, K621, D760</td></tr><tr><td align="left">2</td><td align="center">TF2b</td><td align="char" char=".">&#x02212;9.6</td><td align="char" char=".">13</td><td align="left">K551, Y619, D760, K798, W617, W800, D761, F812, C813, E811, D618, S549, A550</td></tr><tr><td align="left">3</td><td align="center">TF1</td><td align="char" char=".">&#x02212;9.6</td><td align="char" char=".">12</td><td align="left">W617, D761, D760, Y619, R553, K621, P620, F793, D164, S795, K798, D618</td></tr><tr><td align="left">4</td><td align="center">TF2a</td><td align="char" char=".">&#x02212;9.3</td><td align="char" char=".">14</td><td align="left">C813, F812, D761, D760, D618, K798, K551, A550, S549, K621, Y619, W800, W617, E811</td></tr><tr><td align="left">5</td><td align="center">Hesperidin</td><td align="char" char=".">&#x02212;8.8</td><td align="char" char=".">13</td><td align="left">Y619, D618, K798, S795, M794, P793, D164, V166, P620, K621, D623, R555, Y455</td></tr><tr><td align="left">6</td><td align="center">EGCG</td><td align="char" char=".">&#x02212;7.3</td><td align="char" char=".">9</td><td align="left">D623, Y619, K621, S795, C622, D618, M794, P620, K798</td></tr><tr><td align="left">7</td><td align="center">Myricetin</td><td align="char" char=".">&#x02212;7.2</td><td align="char" char=".">10</td><td align="left">W617, W800, D760, E811, K798, D618, Y619, C622, D761, F812</td></tr><tr><td align="left">8</td><td align="center">Quercetagetin</td><td align="char" char=".">&#x02212;7.0</td><td align="char" char=".">8</td><td align="left">R553, K545, K621, D623, C622, D760, P620, Y619</td></tr><tr><td align="left">9</td><td align="center">Remdesivir (Control)</td><td align="char" char=".">&#x02212;7.7</td><td align="char" char=".">13</td><td align="left">R553, K621, C622, D760, E811, W800, K798, P620, Y455, R624, Y619, D618, D761</td></tr><tr><td align="left">10</td><td align="center">GTP (Control)</td><td align="char" char=".">&#x02212;7.9</td><td align="char" char=".">15</td><td align="left">R624, T556, D623, D760, Y619, C622, K621, D452, A554, R553, Y455, R555, D761, D618, P620</td></tr></tbody></table></table-wrap><p>In addition to remdesivir, here we observed that eight dietary polyphenols (TF1, TF2a, TF2b, TF3, hesperidin, EGCG, myricetin and quercetagetin) have significant potential to function as inhibitors of the SARS-CoV-2 RdRp. The top-eight scoring ligands for the SARS-CoV-2 RdRp (as highlighted in <xref rid="t0001" ref-type="table">Table 1</xref>) suggest that these set of natural polyphenols can strongly bind to the catalytic site of the SARS-CoV-2 RdRp and are expected to inhibit the RdRp activity, and thus blocking the replication and preventing viral transcription. Many reports suggest polyphenols have low systemic toxicity, and they are highly beneficial for human health (Bhardwaj et&#x000a0;al., <xref rid="CIT0006" ref-type="bibr">2020</xref>; Cory et&#x000a0;al., <xref rid="CIT0014" ref-type="bibr">2018</xref>). TF1 and its gallate derivatives, collectively known as black tea polyphenols, previously have shown to exert antiviral activity against many viruses such as hepatitis virus and influenza A and B viruses (Chowdhury et&#x000a0;al., <xref rid="CIT0013" ref-type="bibr">2018</xref>). Hesperidin is also known to possess antiviral activity by altering the immune system mainly <italic>via</italic> regulating interferons in the influenza A virus (Randall &#x00026; Goodbourn, <xref rid="CIT0058" ref-type="bibr">2008</xref>). EGCG, a major green tea polyphenol, has several pharmacological properties, including antiviral activity (Carneiro et&#x000a0;al., <xref rid="CIT0009" ref-type="bibr">2016</xref>; Moon &#x00026; Morris, <xref rid="CIT0052" ref-type="bibr">2007</xref>). Similarly, myricetin has also been found to act as an inhibitor of the SARS coronavirus helicase (Yu et&#x000a0;al., <xref rid="CIT0076" ref-type="bibr">2012</xref>). Quercetagetin also showed strong hepatitis C virus replication inhibitory activity <italic>in&#x000a0;vitro</italic> (Ahmed-Belkacem et&#x000a0;al., <xref rid="CIT0003" ref-type="bibr">2014</xref>). Thus, the set dietary polyphenols identified in the present study could be used as repurposed drugs for the treatment of the SARS-CoV-2 infection with further <italic>in-vitro</italic> and <italic>in-vivo</italic> validations.</p></sec></sec><sec id="S0003-S2002" disp-level="2"><label>3.2.</label><title>Molecular dynamics (MD) simulation</title><sec id="S0003-S2002-S3001" disp-level="3"><label>3.2.1.</label><title>Thermodynamic stability and flexibility analysis</title><p>The 150&#x02009;ns production simulations carried out for nine systems (complex of remdesivir, EGCG, TF1, TF2a, TF2b, TF3, hesperidin, myricetin, and quercetagetin with the SARS-CoV-2 RdRp) were stable on the basis of the potential energy and total energy (data not shown) of those complexes. Subsequently, the root-mean-square deviations (RMSDs) of backbone atoms relative to their respective initial positions were calculated for each complex and are shown in <xref ref-type="fig" rid="F0003">Figure 3(A)</xref>. It is evident from <xref ref-type="fig" rid="F0003">Figure 3(A)</xref> that all the nine studied systems drifted from their initial positions during the first 50&#x02009;ns, and after that, they reached equilibrium. The average RMSD values were estimated to be 2.30&#x02009;&#x000c5;, 2.45&#x02009;&#x000c5;, 1.87&#x02009;&#x000c5;, 2.28&#x02009;&#x000c5;, 1.68&#x02009;&#x000c5;, 2.47&#x02009;&#x000c5;, 1.90&#x02009;&#x000c5;, 2.03&#x02009;&#x000c5; and 1.88&#x02009;&#x000c5; for RdRp/remdesivir, RdRp/EGCG, RdRp/TF3, RdRp/TF2b, RdRp/TF2a, RdRp/myricetin, RdRp/quercetagetin, RdRp/hesperidin, and RdRp/TF1 complexes, respectively (<xref rid="t0003" ref-type="table">Table 3</xref>). The least deviation was observed for RdRp/TF2a, while RdRp/myricetin displayed the highest deviation. We also investigated structural variations in the binding site, including all amino acids that fall within a radius of 5 &#x0212b; from the inhibitor, and the same trend was observed (<xref ref-type="fig" rid="F0002">Figure S2A</xref> in the <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07391102.2020.1796810">Supplementary Information</ext-link>). Overall, this suggests the convergence of our simulations.</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>(A) Time evolution of root-mean-square deviations (RMSDs) of backbone atoms and (B) the root-mean-square fluctuations (RMSFs) of C<sub>&#x003b1;</sub> atoms of nine complexes relative to their respective energy minimized structure.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1796810_F0003_C"/></fig><table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>The average backbone RMSD, radius of gyration (RoG), and solvent accessible surface area (SASA) for all nine complexes. The data are reported as average&#x02009;&#x000b1;&#x02009;standard error of the mean (SEM).</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">System</th><th align="center">RMSD (&#x000c5;)</th><th align="center">RoG (&#x000c5;)</th><th align="center">SASA (&#x000c5;<sup>2</sup>)</th></tr></thead><tbody valign="top"><tr><td align="left">RdRp/Remdesivir</td><td align="left">2.30&#x02009;&#x000b1;&#x02009;0.03</td><td align="char" char=".">29.96&#x02009;&#x000b1;&#x02009;0.02</td><td align="char" char=".">34973.20&#x02009;&#x000b1;&#x02009;91.56</td></tr><tr><td align="left">RdRp/EGCG</td><td align="left">2.45&#x02009;&#x000b1;&#x02009;0.05</td><td align="char" char=".">29.52&#x02009;&#x000b1;&#x02009;0.06</td><td align="char" char=".">35026.03&#x02009;&#x000b1;&#x02009;63.52</td></tr><tr><td align="left">RdRp/TF3</td><td align="left">1.87&#x02009;&#x000b1;&#x02009;0.02</td><td align="char" char=".">29.60&#x02009;&#x000b1;&#x02009;0.01</td><td align="char" char=".">34080.16&#x02009;&#x000b1;&#x02009;53.41</td></tr><tr><td align="left">RdRp/TF2b</td><td align="left">2.28&#x02009;&#x000b1;&#x02009;0.01</td><td align="char" char=".">29.86&#x02009;&#x000b1;&#x02009;0.02</td><td align="char" char=".">35462.92&#x02009;&#x000b1;&#x02009;50.40</td></tr><tr><td align="left">RdRp/TF2a</td><td align="left">1.68&#x02009;&#x000b1;&#x02009;0.02</td><td align="char" char=".">29.75&#x02009;&#x000b1;&#x02009;0.02</td><td align="char" char=".">34312.55&#x02009;&#x000b1;&#x02009;112.89</td></tr><tr><td align="left">RdRp/Myricetin</td><td align="left">2.47&#x02009;&#x000b1;&#x02009;0.03</td><td align="char" char=".">29.88&#x02009;&#x000b1;&#x02009;0.01</td><td align="char" char=".">35395.35&#x02009;&#x000b1;&#x02009;104.67</td></tr><tr><td align="left">RdRp/Quercetagetin</td><td align="left">1.90&#x02009;&#x000b1;&#x02009;0.03</td><td align="char" char=".">29.84&#x02009;&#x000b1;&#x02009;0.01</td><td align="char" char=".">34618.65&#x02009;&#x000b1;&#x02009;51.25</td></tr><tr><td align="left">RdRp/Hesperidin</td><td align="left">2.03&#x02009;&#x000b1;&#x02009;0.04</td><td align="char" char=".">29.74&#x02009;&#x000b1;&#x02009;0.02</td><td align="char" char=".">34554.08&#x02009;&#x000b1;&#x02009;47.25</td></tr><tr><td align="left">RdRp/TF1</td><td align="left">1.88&#x02009;&#x000b1;&#x02009;0.03</td><td align="char" char=".">29.86&#x02009;&#x000b1;&#x02009;0.01</td><td align="char" char=".">34420.69&#x02009;&#x000b1;&#x02009;56.90</td></tr></tbody></table></table-wrap><p>Next, we investigated the structural stability of remdesivir and eight polyphenols by estimating the temporal RMSDs of heavy atoms relative to their respective initial coordinates (see <xref ref-type="fig" rid="F0002">Figure S2B</xref> in the <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07391102.2020.1796810">Supplementary Information</ext-link>). It is evident from <xref ref-type="fig" rid="F0002">Figure S2B</xref> that EGCG, myricetin, quercetagetin, TF1, TF3 displayed a rigid behavior in the bound form with an average RMSD of &#x0003c; 1.0&#x02009;&#x000c5;. However, remdesivir, TF2a, TF2b and hesperidin showed higher fluctuations as compared to the abovementioned polyphenols, and an average RMSD of &#x0003e; 2.0&#x02009;&#x000c5; was noted.</p><p>To identify the regions which are flexible, the root-mean-square fluctuations (RMSFs) of C<sub>&#x003b1;</sub> atoms of each residue are calculated and shown in <xref ref-type="fig" rid="F0003">Figure 3(B)</xref>. From this analysis, we can get a better insight into what extent the binding of remdesivir and natural polyphenols affects the residual flexibility of RdRp (mainly Nsp12). <xref ref-type="fig" rid="F0003">Figure 3(B)</xref> indicates that RdRp/remdesivir and RdRp-polyphenols shared a similar RMSF pattern. Notable dynamic fluctuations were located in the non-active site domain, including both <italic>N</italic>-terminals and <italic>C</italic>-terminal. Regions around Asn150, Asp260, Arg305, Asn360, and Phe440 are found to be more flexible compared to the other area for all complexes. The binding pocket residues, such as Asp452, Lys545, Lys551, Tyr455, Arg553, Ala554, Arg555, Thr556, Asp618, Tyr619, pro620, Lys621, Cys622, Asp623 Arg624, Asn691, Asp760, Asp761, Phe793, Met794, Ser795, Lys798, Trp800, Glu811, Phe812, and Ser814 exhibited considerably low fluctuations for all the RdRp-inhibitor complexes. In the case of RdRp/TF3 and RdRp/TF2a, the binding site residues displayed lesser fluctuations compared to the other RdRp-polyphenol complexes. This suggests that TF3 and TF2a are likely to be bound to RdRp more strongly than the other polyphenols.</p><p>Since the radius of gyration (RoG) helps us to understand the protein structural compactness, RoG of each complex was monitored and represented in <xref ref-type="fig" rid="F0003">Figure S3A</xref> in the <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07391102.2020.1796810">Supplementary Information</ext-link>. The average values of RoG are 29.96&#x02009;&#x000c5;, 29.52&#x02009;&#x000c5;, 29.60&#x02009;&#x000c5;, 29.86&#x02009;&#x000c5;, 29.75&#x02009;&#x000c5;, 29.88&#x02009;&#x000c5;, 29.84&#x02009;&#x000c5;, 29.74&#x02009;&#x000c5; and 29.86&#x02009;&#x000c5; for RdRp complexed with remdesivir, EGCG, TF3, TF2b, TF2a, myricetin, quercetagetin, hesperidin and TF1 respectively (<xref rid="t0003" ref-type="table">Table 3</xref>). This suggests that the structural compactness remained unchanged during simulations. Finally, the solvent-accessible surface area (SASA) was also explored, and the time evolution of SASA for four RdRp-polyphenol complexes are shown in <xref ref-type="fig" rid="F0003">Figure S3B</xref> in the <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07391102.2020.1796810">Supplementary Information</ext-link>. The average values of SASA are reported in <xref rid="t0003" ref-type="table">Table 3</xref>. Binding of an inhibitor to the substrate changes SASA and sometimes could greatly affect the protein structure. Here, a relatively higher SASA value was obtained for RdRp/TF2b (35462.9 &#x000c5;<sup>2</sup>) compared to the other RdRp/inhibitor complexes. On the other hand, the lowest SASA value was noted for RdRp/TF3 (34080.2 &#x000c5;<sup>2</sup>). Thus, it can be suggested that the binding of TF3 could potentially reduce protein expansion.</p></sec><sec id="S0003-S2002-S3002" disp-level="3"><label>3.2.2.</label><title>Binding free energy analysis</title><p>We predicted the binding free energy of all nine complexes by utilizing the MM-PBSA scheme, and four polyphenols, namely EGCG, TF3, TF2b, and TF2a, displayed a higher estimated affinity compared to remdesivir as depicted in <xref ref-type="fig" rid="F0004">Figure 4</xref>. Various components of the binding free energy of EGCG, TF3, TF2b, and TF2a are reported in <xref rid="t0004" ref-type="table">Table 4</xref>. The remaining four polyphenols which showed lower estimated affinity compare to remdesivir are shown in <xref rid="t0002" ref-type="table">Table S2</xref> in <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07391102.2020.1796810">Supplementary Information</ext-link>. It can be noted from <xref ref-type="fig" rid="F0004">Figure 4</xref> that the intermolecular van der Waals (&#x00394;<italic>E</italic><sub>vdW</sub>) and electrostatic (&#x00394;<italic>E</italic><sub>elec</sub>) terms are favorable for the ligand binding, whereas the desolvation of polar groups (&#x00394;<italic>G</italic><sub>pol</sub>) opposes the complex formation. Non-polar solvation free energy (&#x00394;<italic>G</italic><sub>np</sub>) is favorable to the binding for all cases. A similar trend was observed in our earlier study (Sk, Roy, Jonniya, et&#x000a0;al., <xref rid="CIT0062" ref-type="bibr">2020</xref>).</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Energy components (kcal/mol) for the binding of remdesivir and four polyphenols to RdRp receptor. &#x00394;<italic>E</italic><sub>vdW</sub>, van der Waals interaction; &#x00394;<italic>E</italic><sub>ele</sub>, electrostatic interaction in the gas phase; &#x00394;<italic>G</italic><sub>pol</sub>, polar solvation energy; &#x00394;<italic>G</italic><sub>np</sub>, non-polar solvation energy, and &#x00394;<italic>G</italic><sub>bind</sub>, estimated binding affinity.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1796810_F0004_C"/></fig><table-wrap id="t0004" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Energetic components of the binding free energy of RdRp and natural polyphenols along with remdesivir complexes in kcal/mol. Data are represented as average&#x02009;&#x000b1;&#x02009;SEM.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Components</th><th align="center">Remdesivir</th><th align="center">EGCG</th><th align="center">TF3</th><th align="center">TF2b</th><th align="center">TF2a</th></tr></thead><tbody valign="top"><tr><td align="left">&#x00394;<italic toggle="yes">E</italic><bold><sub>vdW</sub></bold></td><td align="char" char="&#x000b1;">&#x02212;31.85&#x02009;&#x000b1;&#x02009;0.15</td><td align="char" char="&#x000b1;">&#x02212;25.11&#x02009;&#x000b1;&#x02009;0.18</td><td align="char" char="&#x000b1;">&#x02212;37.82&#x02009;&#x000b1;&#x02009;0.21</td><td align="char" char="&#x000b1;">&#x02212;30.66&#x02009;&#x000b1;&#x02009;0.23</td><td align="char" char="&#x000b1;">&#x02212;22.55&#x02009;&#x000b1;&#x02009;0.19</td></tr><tr><td align="left">&#x00394;<italic toggle="yes">E</italic><bold><sub>elec</sub></bold></td><td align="char" char="&#x000b1;">&#x02212;98.40&#x02009;&#x000b1;&#x02009;0.70</td><td align="char" char="&#x000b1;">&#x02212;69.38&#x02009;&#x000b1;&#x02009;0.73</td><td align="char" char="&#x000b1;">&#x02212;123.63&#x02009;&#x000b1;&#x02009;0.88</td><td align="char" char="&#x000b1;">&#x02212;47.18&#x02009;&#x000b1;&#x02009;0.64</td><td align="char" char="&#x000b1;">&#x02212;95.28&#x02009;&#x000b1;&#x02009;1.27</td></tr><tr><td align="left">&#x00394;<italic toggle="yes">G</italic><bold><sub>pol</sub></bold></td><td align="char" char="&#x000b1;">109.97&#x02009;&#x000b1;&#x02009;0.57</td><td align="char" char="&#x000b1;">71.62&#x02009;&#x000b1;&#x02009;0.48</td><td align="char" char="&#x000b1;">124.47&#x02009;&#x000b1;&#x02009;0.58</td><td align="char" char="&#x000b1;">55.01&#x02009;&#x000b1;&#x02009;0.49</td><td align="char" char="&#x000b1;">94.94&#x02009;&#x000b1;&#x02009;1.10</td></tr><tr><td align="left">&#x00394;<italic toggle="yes">G</italic><bold><sub>np</sub></bold></td><td align="char" char="&#x000b1;">&#x02212;4.29&#x02009;&#x000b1;&#x02009;0.01</td><td align="char" char="&#x000b1;">&#x02212;4.15&#x02009;&#x000b1;&#x02009;0.01</td><td align="char" char="&#x000b1;">&#x02212;5.29&#x02009;&#x000b1;&#x02009;0.01</td><td align="char" char="&#x000b1;">&#x02212;3.91&#x02009;&#x000b1;&#x02009;0.01</td><td align="char" char="&#x000b1;">&#x02212;4.28&#x02009;&#x000b1;&#x02009;0.02</td></tr><tr><td align="left"><xref ref-type="table-fn" rid="TF1"><sup>a</sup></xref>&#x00394;<italic toggle="yes">G</italic><bold><sub>solv</sub></bold></td><td align="char" char="&#x000b1;">105.68&#x02009;&#x000b1;&#x02009;0.57</td><td align="char" char="&#x000b1;">67.47&#x02009;&#x000b1;&#x02009;0.48</td><td align="char" char="&#x000b1;">119.18&#x02009;&#x000b1;&#x02009;0.58</td><td align="char" char="&#x000b1;">51.1&#x02009;&#x000b1;&#x02009;0.49</td><td align="char" char="&#x000b1;">90.66&#x02009;&#x000b1;&#x02009;1.10</td></tr><tr><td align="left"><xref ref-type="table-fn" rid="TF2"><sup>b</sup></xref>&#x00394;<italic toggle="yes">G</italic><bold><sub>pol + elec</sub></bold></td><td align="char" char="&#x000b1;">11.57&#x02009;&#x000b1;&#x02009;0.90</td><td align="char" char="&#x000b1;">2.24&#x02009;&#x000b1;&#x02009;0.87</td><td align="char" char="&#x000b1;">0.84&#x02009;&#x000b1;&#x02009;1.05</td><td align="char" char="&#x000b1;">7.83&#x02009;&#x000b1;&#x02009;0.80</td><td align="char" char="&#x000b1;">&#x02212;0.34&#x02009;&#x000b1;&#x02009;1.68</td></tr><tr><td align="left"><xref ref-type="table-fn" rid="TF3"><sup>c</sup></xref>&#x00394;<italic toggle="yes">E</italic><bold><sub>MM</sub></bold></td><td align="char" char="&#x000b1;">&#x02212;130.25&#x02009;&#x000b1;&#x02009;0.71</td><td align="char" char="&#x000b1;">&#x02212;94.49&#x02009;&#x000b1;&#x02009;0.75</td><td align="char" char="&#x000b1;">&#x02212;161.45&#x02009;&#x000b1;&#x02009;0.90</td><td align="char" char="&#x000b1;">&#x02212;77.84&#x02009;&#x000b1;&#x02009;0.68</td><td align="char" char="&#x000b1;">&#x02212;117.83&#x02009;&#x000b1;&#x02009;1.28</td></tr><tr><td align="left">&#x00394;<italic toggle="yes">G</italic><bold><sub>bind</sub><sup>Sim</sup></bold></td><td align="char" char="&#x000b1;">&#x02212;24.57&#x02009;&#x000b1;&#x02009;0.91</td><td align="char" char="&#x000b1;">&#x02212;27.02&#x02009;&#x000b1;&#x02009;0.89</td><td align="char" char="&#x000b1;">&#x02212;42.27&#x02009;&#x000b1;&#x02009;1.07</td><td align="char" char="&#x000b1;">&#x02212;26.74&#x02009;&#x000b1;&#x02009;0.83</td><td align="char" char="&#x000b1;">&#x02212;27.17&#x02009;&#x000b1;&#x02009;1.69</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><label><sup>a</sup></label><p>&#x00394;<italic>G</italic><sub>solv</sub> = &#x00394;<italic>G</italic><sub>np</sub> + &#x00394;<italic>G</italic><sub>pol</sub>,</p></fn><fn id="TF2"><label><sup>b</sup></label><p>&#x00394;<italic>G</italic><sub>pol + elec</sub> = &#x00394;<italic>E</italic><sub>elec</sub> + &#x00394;<italic>G</italic><sub>pol</sub>,</p></fn><fn id="TF3"><label><sup>c</sup></label><p>&#x00394;<italic>E</italic><sub>MM</sub> = &#x00394;<italic>E</italic><sub>vdW</sub> + &#x00394;<italic>E</italic><sub>elec</sub>.</p></fn></table-wrap-foot></table-wrap><p>It is evident from <xref rid="t0004" ref-type="table">Table 4</xref> that for all complexes, &#x00394;<italic>E</italic><sub>vdW</sub> varies between &#x02212;22.55&#x02009;kcal/mol and &#x02212;37.82&#x02009;kcal/mol while &#x00394;<italic>E</italic><sub>elec</sub> ranges from &#x02212;47.18&#x02009;kcal/mol to &#x02212;123.63&#x02009;kcal/mol. Furthermore, in the cases of RdRp/remdesivir, RdRp/EGCG, RdRp/TF3, and RdRp/TF2b, &#x00394;<italic>E</italic><sub>ele</sub> is over-compensated by the desolvation energy (&#x00394;<italic>G</italic><sub>pol</sub>), indicating that the sum of these two components, &#x00394;<italic>G</italic><sub>pol + elec,</sub> is unfavorable to the binding and varies between 0.84&#x02009;kcal/mol and 11.57&#x02009;kcal/mol (see <xref rid="t0004" ref-type="table">Table 4</xref>) and similar results are found for RdRp/myricetin, RdRp/quercetagetin, RdRp/hesperidin, and RdRp/TF1 (see <xref rid="t0002" ref-type="table">Table S2</xref> in <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07391102.2020.1796810">Supplementary Information</ext-link>). In contrast, in the case of RdRp/TF2a, &#x00394;<italic>G</italic><sub>pol + elec</sub>, is favorable to the complexation (&#x00394;<italic>G</italic><sub>pol + elec</sub> = &#x02212;0.34&#x02009;kcal/mol). Overall, this suggests that the complex formation is mainly driven by the van der Waals interactions between polyphenols as well as remdesivir and RdRp. Therefore, hydrophobic residues in the binding pocket played a crucial role in the complexation process.</p><p>The estimated binding free energy (&#x00394;G<sub>bind</sub>) of remdesivir, EGCG, TF3, TF2b, and TF2a were &#x02212;24.57, &#x02212;27.02, &#x02212;42.27, &#x02212;26.74 and &#x02212;27.17&#x02009;kcal/mol, respectively (<xref rid="t0004" ref-type="table">Table 4</xref>) and myricetin, quercetagetin, hesperidin and TF1 show lower binding affinity compared to that of remdesivir (<xref rid="t0002" ref-type="table">Table S2</xref> in the <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07391102.2020.1796810">Supplementary Information</ext-link>). This suggests that polyphenol TF3 binds most strongly to RdRp, followed by TF2a and EGCG. The potency of the five inhibitors decreases in the following order: TF3&#x02009;&#x0003e;&#x02009;TF2a&#x02009;&#x0003e;&#x02009;EGCG&#x02009;&#x0003e;&#x02009;TF2b&#x02009;&#x0003e;&#x02009;remdesivir. TF3 binds most strongly to RdRp because both &#x00394;<italic>E</italic><sub>vdW</sub> and &#x00394;<italic>E</italic><sub>elec</sub> are more favorable to the binding compared to the other inhibitors. Similarly, TF2a binds more strongly to RdRp compared to EGCG or TF2b because &#x00394;<italic>G</italic><sub>pol + elec</sub> is favorable for TF2a (&#x00394;<italic>G</italic><sub>pol + elec</sub> = &#x02212;0.34&#x02009;kcal/mol) while it is found to be unfavorable for EGCG (&#x00394;<italic>G</italic><sub>pol + elec</sub> = 2.24&#x02009;kcal/mol) and TF2b (&#x00394;<italic>G</italic><sub>pol + elec</sub> = 7.83&#x02009;kcal/mol).</p></sec><sec id="S0003-S2002-S3003" disp-level="3"><label>3.2.3.</label><title>Essential residues for polyphenols binding</title><p>Further, to gain a deeper insight into the best four RdRp/polyphenols and remdesivir interaction pattern, the total binding free energy was decomposed into polyphenols-residue pair based on the MM-GBSA scheme. The approach of per-residue based contributions is useful to determine the binding mechanisms of an inhibitor at an atomistic level, and it also reveals the individual residue contributions. The different energy contributions from the backbone and side-chain of each residue are shown in <xref ref-type="fig" rid="F0005">Figure 5</xref> and listed in <xref rid="t0005" ref-type="table">Table 5</xref>.</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Decomposition of the binding free energy into contributions from individual residues for RdRp complexed with remdesivir, EGCG, TF3, TF2b and TF2a.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1796810_F0005_C"/></fig><table-wrap id="t0005" orientation="portrait" position="float"><label>Table 5.</label><caption><p>Per-residue based decomposition of binding free energy for the complex of remdesivir, EGCG, TF3, TF2a and TF2b with the SARS-CoV-2 RdRp.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Residue</th><th align="center">T<sub>vdW</sub></th><th align="center">T<sub>elec</sub></th><th align="center">T<sub>pol</sub></th><th align="center">T<sub>np</sub></th><th align="center">T<sub>side_chain</sub></th><th align="center">T<sub>backbone</sub></th><th align="center">T<sub>total</sub></th></tr></thead><tbody valign="top"><tr><td colspan="8" align="center">RdRp/Remdesivir</td></tr><tr><td align="left">Asp761</td><td align="char" char=".">1.05</td><td align="char" char=".">&#x02212;21.73</td><td align="char" char=".">18.81</td><td align="char" char=".">&#x02212;0.14</td><td align="char" char=".">&#x02212;1.82</td><td align="char" char=".">&#x02212;0.19</td><td align="char" char=".">&#x02212;2.01</td></tr><tr><td align="left">Lys798</td><td align="char" char=".">&#x02212;2.74</td><td align="char" char=".">&#x02212;4.28</td><td align="char" char=".">5.74</td><td align="char" char=".">&#x02212;0.47</td><td align="char" char=".">&#x02212;1.76</td><td align="char" char=".">0.01</td><td align="char" char=".">&#x02212;1.75</td></tr><tr><td align="left">Pro620</td><td align="char" char=".">&#x02212;1.42</td><td align="char" char=".">&#x02212;1.15</td><td align="char" char=".">1.16</td><td align="char" char=".">&#x02212;0.18</td><td align="char" char=".">&#x02212;1.26</td><td align="char" char=".">&#x02212;0.33</td><td align="char" char=".">&#x02212;1.59</td></tr><tr><td align="left">Asp760</td><td align="char" char=".">&#x02212;0.57</td><td align="char" char=".">&#x02212;4.27</td><td align="char" char=".">4.24</td><td align="char" char=".">&#x02212;0.12</td><td align="char" char=".">&#x02212;0.20</td><td align="char" char=".">&#x02212;0.52</td><td align="char" char=".">&#x02212;0.72</td></tr><tr><td align="left">Arg553</td><td align="char" char=".">&#x02212;2.07</td><td align="char" char=".">&#x02212;3.71</td><td align="char" char=".">5.61</td><td align="char" char=".">&#x02212;0.51</td><td align="char" char=".">&#x02212;0.76</td><td align="char" char=".">0.08</td><td align="char" char=".">&#x02212;0.68</td></tr><tr><td colspan="8" align="center">RdRp/EGCG</td></tr><tr><td align="left">Asp452</td><td align="char" char=".">1.65</td><td align="char" char=".">&#x02212;16.48</td><td align="char" char=".">9.85</td><td align="char" char=".">&#x02212;0.08</td><td align="char" char=".">&#x02212;5.15</td><td align="char" char=".">0.09</td><td align="char" char=".">&#x02212;5.06</td></tr><tr><td align="left">Arg553</td><td align="char" char=".">&#x02212;3.83</td><td align="char" char=".">&#x02212;4.84</td><td align="char" char=".">6.59</td><td align="char" char=".">&#x02212;0.59</td><td align="char" char=".">&#x02212;2.68</td><td align="char" char=".">0.01</td><td align="char" char=".">&#x02212;2.67</td></tr><tr><td align="left">Pro620</td><td align="char" char=".">&#x02212;1.64</td><td align="char" char=".">&#x02212;0.41</td><td align="char" char=".">0.51</td><td align="char" char=".">&#x02212;0.33</td><td align="char" char=".">&#x02212;1.62</td><td align="char" char=".">&#x02212;0.25</td><td align="char" char=".">&#x02212;1.87</td></tr><tr><td align="left">Asp618</td><td align="char" char=".">0.49</td><td align="char" char=".">&#x02212;8.14</td><td align="char" char=".">6.66</td><td align="char" char=".">&#x02212;0.09</td><td align="char" char=".">&#x02212;1.13</td><td align="char" char=".">&#x02212;0.05</td><td align="char" char=".">&#x02212;1.08</td></tr><tr><td align="left">Lys621</td><td align="char" char=".">&#x02212;2.26</td><td align="char" char=".">&#x02212;5.12</td><td align="char" char=".">6.92</td><td align="char" char=".">&#x02212;0.50</td><td align="char" char=".">&#x02212;0.87</td><td align="char" char=".">&#x02212;0.09</td><td align="char" char=".">&#x02212;0.96</td></tr><tr><td colspan="8" align="center">RdRp/TF3</td></tr><tr><td align="left">Asp761</td><td align="char" char=".">2.52</td><td align="char" char=".">&#x02212;30.13</td><td align="char" char=".">22.11</td><td align="char" char=".">&#x02212;0.25</td><td align="char" char=".">&#x02212;5.54</td><td align="char" char=".">&#x02212;0.21</td><td align="char" char=".">&#x02212;5.75</td></tr><tr><td align="left">Arg836</td><td align="char" char=".">&#x02212;0.83</td><td align="char" char=".">&#x02212;14.95</td><td align="char" char=".">12.29</td><td align="char" char=".">&#x02212;0.37</td><td align="char" char=".">&#x02212;3.85</td><td align="char" char=".">&#x02212;0.01</td><td align="char" char=".">&#x02212;3.86</td></tr><tr><td align="left">Arg555</td><td align="char" char=".">&#x02212;5.80</td><td align="char" char=".">&#x02212;4.00</td><td align="char" char=".">7.29</td><td align="char" char=".">&#x02212;0.70</td><td align="char" char=".">&#x02212;2.98</td><td align="char" char=".">&#x02212;0.23</td><td align="char" char=".">&#x02212;3.21</td></tr><tr><td align="left">Thr556</td><td align="char" char=".">&#x02212;0.20</td><td align="char" char=".">&#x02212;3.96</td><td align="char" char=".">2.44</td><td align="char" char=".">&#x02212;0.13</td><td align="char" char=".">&#x02212;0.21</td><td align="char" char=".">&#x02212;1.64</td><td align="char" char=".">&#x02212;1.85</td></tr><tr><td align="left">Ile548</td><td align="char" char=".">&#x02212;1.03</td><td align="char" char=".">&#x02212;0.08</td><td align="char" char=".">0.12</td><td align="char" char=".">&#x02212;0.13</td><td align="char" char=".">&#x02212;0.65</td><td align="char" char=".">&#x02212;0.47</td><td align="char" char=".">&#x02212;1.12</td></tr><tr><td align="left">Ser814</td><td align="char" char=".">&#x02212;1.67</td><td align="char" char=".">0.09</td><td align="char" char=".">0.78</td><td align="char" char=".">&#x02212;0.08</td><td align="char" char=".">&#x02212;0.48</td><td align="char" char=".">&#x02212;0.40</td><td align="char" char=".">&#x02212;0.88</td></tr><tr><td align="left">Val557</td><td align="char" char=".">&#x02212;0.65</td><td align="char" char=".">&#x02212;0.16</td><td align="char" char=".">0.17</td><td align="char" char=".">&#x02212;0.24</td><td align="char" char=".">&#x02212;0.65</td><td align="char" char=".">&#x02212;0.23</td><td align="char" char=".">&#x02212;0.88</td></tr><tr><td colspan="8" align="center">RdRp/TF2b</td></tr><tr><td align="left">His816</td><td align="char" char=".">&#x02212;3.00</td><td align="char" char=".">&#x02212;0.81</td><td align="char" char=".">1.69</td><td align="char" char=".">&#x02212;0.32</td><td align="char" char=".">&#x02212;1.63</td><td align="char" char=".">&#x02212;0.81</td><td align="char" char=".">&#x02212;2.44</td></tr><tr><td align="left">Asp833</td><td align="char" char=".">&#x02212;1.29</td><td align="char" char=".">&#x02212;0.23</td><td align="char" char=".">0.46</td><td align="char" char=".">&#x02212;0.18</td><td align="char" char=".">&#x02212;0.21</td><td align="char" char=".">&#x02212;1.03</td><td align="char" char=".">&#x02212;1.24</td></tr><tr><td align="left">Tyr877</td><td align="char" char=".">&#x02212;0.92</td><td align="char" char=".">&#x02212;2.06</td><td align="char" char=".">2.06</td><td align="char" char=".">&#x02212;0.27</td><td align="char" char=".">&#x02212;0.43</td><td align="char" char=".">&#x02212;0.76</td><td align="char" char=".">&#x02212;1.19</td></tr><tr><td align="left">Glu811</td><td align="char" char=".">0.22</td><td align="char" char=".">&#x02212;9.24</td><td align="char" char=".">8.11</td><td align="char" char=".">&#x02212;0.13</td><td align="char" char=".">&#x02212;2.07</td><td align="char" char=".">1.03</td><td align="char" char=".">&#x02212;1.04</td></tr><tr><td align="left">His810</td><td align="char" char=".">&#x02212;1.88</td><td align="char" char=".">&#x02212;0.41</td><td align="char" char=".">1.66</td><td align="char" char=".">&#x02212;0.34</td><td align="char" char=".">&#x02212;0.10</td><td align="char" char=".">&#x02212;0.85</td><td align="char" char=".">&#x02212;0.95</td></tr><tr><td align="left">Tyr831</td><td align="char" char=".">&#x02212;1.51</td><td align="char" char=".">&#x02212;0.36</td><td align="char" char=".">1.19</td><td align="char" char=".">&#x02212;0.13</td><td align="char" char=".">&#x02212;0.21</td><td align="char" char=".">&#x02212;0.60</td><td align="char" char=".">&#x02212;0.81</td></tr><tr><td align="left">Asn815</td><td align="char" char=".">&#x02212;0.60</td><td align="char" char=".">&#x02212;0.27</td><td align="char" char=".">0.09</td><td align="char" char=".">&#x02212;0.01</td><td align="char" char=".">&#x02212;0.25</td><td align="char" char=".">&#x02212;0.54</td><td align="char" char=".">&#x02212;0.79</td></tr><tr><td colspan="8" align="center">RdRp/TF2a</td></tr><tr><td align="left">Asp618</td><td align="char" char=".">2.63</td><td align="char" char=".">&#x02212;20.71</td><td align="char" char=".">13.40</td><td align="char" char=".">&#x02212;0.17</td><td align="char" char=".">&#x02212;4.84</td><td align="char" char=".">&#x02212;0.01</td><td align="char" char=".">&#x02212;4.85</td></tr><tr><td align="left">Arg553</td><td align="char" char=".">&#x02212;3.80</td><td align="char" char=".">&#x02212;6.52</td><td align="char" char=".">7.55</td><td align="char" char=".">&#x02212;0.69</td><td align="char" char=".">&#x02212;2.68</td><td align="char" char=".">&#x02212;0.78</td><td align="char" char=".">&#x02212;3.46</td></tr><tr><td align="left">Lys551</td><td align="char" char=".">&#x02212;2.23</td><td align="char" char=".">&#x02212;0.80</td><td align="char" char=".">2.23</td><td align="char" char=".">&#x02212;0.45</td><td align="char" char=".">&#x02212;0.84</td><td align="char" char=".">&#x02212;0.41</td><td align="char" char=".">&#x02212;1.25</td></tr><tr><td align="left">Arg555</td><td align="char" char=".">&#x02212;1.33</td><td align="char" char=".">&#x02212;0.62</td><td align="char" char=".">1.05</td><td align="char" char=".">&#x02212;0.27</td><td align="char" char=".">&#x02212;1.12</td><td align="char" char=".">&#x02212;0.05</td><td align="char" char=".">&#x02212;1.17</td></tr><tr><td align="left">Glu167</td><td align="char" char=".">0.42</td><td align="char" char=".">&#x02212;6.82</td><td align="char" char=".">5.92</td><td align="char" char=".">&#x02212;0.12</td><td align="char" char=".">&#x02212;0.61</td><td align="char" char=".">0.01</td><td align="char" char=".">&#x02212;0.60</td></tr></tbody></table></table-wrap><p>As shown in <xref ref-type="fig" rid="F0005">Figure 5</xref>, it was observed that residues favoring the binding of the polyphenols with RdRp include Asp452, Arg553, Arg555, Val557, Asp618, Pro620, Lys621, Asp623, Arg624, Asp760, Asp761, and Glu811, Asp833, and Arg836. Most of these residues are located in the binding site of RdRp and can form direct contacts with polyphenols and remdesivir. <xref ref-type="fig" rid="F0005">Figure 5</xref> shows that amino acids Pro620, Asp761 and Lys798 for RdRp/remdesivir; Asp452, Arg553, Pro620 and Lys621 for RdRp/EGCG; Ile548, Arg555, Thr556, Asp761 and Arg836 for RdRp/TF3; Glu811, His816, Asp833 and Tyr877 for RdRp/TF2b; Lys551, Arg553, Arg555 and Asp618 for RdRp/TF2a contributed more favorably towards the binding by contributing more than &#x02212;1.0&#x02009;kcal/mol in size.</p><p>To complement the energetic analysis, we performed MD trajectory-based hydrogen bond (h-bond) analysis for all five complexes, and the h-bonds with occupancy are listed in <xref rid="t0006" ref-type="table">Table 6</xref>. The h-bonds were determined by setting the acceptor-donor distance of &#x02264; 3.5&#x02009;&#x000c5;, and the angle cut off &#x02265; 120<sup>0</sup>. Important h-bonds between RdRp-inhibitors are shown in <xref ref-type="fig" rid="F0006">Figure 6</xref>. In the case of RdRp/remdesivir, key residues involved in the hydrogen bonding are Asp761, Asp760, and Ser759, respectively. Asp760 is found to form two h-bonds with remdesivir (Asp760@OD2 - Lig@O7, Asp760@OD2 - Lig@O6) with an occupancy of more than 15% (see <xref rid="t0006" ref-type="table">Table 6</xref> and <xref ref-type="fig" rid="F0006">Figure 6</xref>). In the case of RdRp/EGCG, both Asp618 and Asp760 form two h-bonds with the ligand with an occupancy in the range of 16.09 to 30.17%. On the other hand, Asp761 form an h-bond with TF3 (Asp761@OD1 - Lig@O11) with an occupancy of 69.84%, while Arg836 forms two h-bonds with the ligand (Arg836@NH2 - Lig@O14, Arg836@NE - Lig@O14) with an occupancy of 52.66%, and 48.70%, respectively. Glu811, Thr556 and Asp761 also formed h-bonds with the ligand during our simulations with an occupancy varying in the range of 44% to 58% (see <xref rid="t0006" ref-type="table">Table 6</xref>). In the case of RdRp/TF2b, Glu811 is found to form two strong h&#x02013;bonds with the ligand (Glu811@OE1 &#x02013; Lig@O7, Glu811@OE2 &#x02013; Lig@O7) with an occupancy of 22.45% and 18.89%, respectively. On the other hand, it can be observed from <xref rid="t0006" ref-type="table">Table 6</xref> that Pro832 and Tyr877 form strong h-bonds (Pro832@O -Lig@O8 and Lig@O10 -Tyr877@OH) with increased occupancy (&#x0003e; 24%). Finally, in the case of RdRp/TF2a, Asp618 is found to form two strong h-bonds with the TF2a (Asp618@OD1 &#x02013; Lig@O10, Asp618@OD1 &#x02013; Lig@O11) with an occupancy of 38.68% and 38.38%, respectively. Asp760 also forms a h-bond (Asp760@O &#x02013; Lig@O11) with an occupancy of 20.83%.</p><fig id="F0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>Five main hydrogen bond interactions between ligands and RdRp.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1796810_F0006_C"/></fig><table-wrap id="t0006" orientation="portrait" position="float"><label>Table 6.</label><caption><p>Main hydrogen bond interactions formed by RdRp with remdesivir and polyphenols along with the corresponding average distance and percentage of occupancy determined using the trajectories of production simulations.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Acceptor</th><th align="center">Donor</th><th align="center">Avg. Distance (&#x000c5;)</th><th align="center">Occupancy (%)</th></tr></thead><tbody valign="top"><tr><td colspan="4" align="center">RdRp/Remdesivir</td></tr><tr><td align="left">Asp760@OD2</td><td align="left">Lig@O7</td><td align="char" char=".">2.66</td><td align="char" char=".">19.46</td></tr><tr><td align="left">Asp761@OD1</td><td align="left">Lig@O7</td><td align="char" char=".">2.65</td><td align="char" char=".">17.70</td></tr><tr><td align="left">Asp761@OD2</td><td align="left">Lig@O6</td><td align="char" char=".">2.63</td><td align="char" char=".">16.86</td></tr><tr><td align="left">Asp760@OD2</td><td align="left">Lig@O6</td><td align="char" char=".">2.65</td><td align="char" char=".">16.65</td></tr><tr><td align="left">Lig@O6</td><td align="left">Ser759@OG</td><td align="char" char=".">2.80</td><td align="char" char=".">11.63</td></tr><tr><td align="left">Asp760@OD1</td><td align="left">Lig@O7</td><td align="char" char=".">2.66</td><td align="char" char=".">10.59</td></tr><tr><td colspan="4" align="center">RdRp/EGCG</td></tr><tr><td align="left">Asp618@OD1</td><td align="left">Lig@O5</td><td align="char" char=".">2.61</td><td align="char" char=".">30.13</td></tr><tr><td align="left">Asp618@OD1</td><td align="left">Lig@O6</td><td align="char" char=".">2.61</td><td align="char" char=".">29.28</td></tr><tr><td align="left">Asp618@OD2</td><td align="left">Lig@O5</td><td align="char" char=".">2.61</td><td align="char" char=".">18.25</td></tr><tr><td align="left">Asp618@OD2</td><td align="left">Lig@O6</td><td align="char" char=".">2.61</td><td align="char" char=".">17.38</td></tr><tr><td align="left">Asp760@OD1</td><td align="left">Lig@O5</td><td align="char" char=".">2.63</td><td align="char" char=".">16.09</td></tr><tr><td align="left">Tyr455@OH</td><td align="left">Lig@O11</td><td align="char" char=".">2.83</td><td align="char" char=".">10.97</td></tr><tr><td colspan="4" align="center">RdRp/TF3</td></tr><tr><td align="left">Asp761@OD1</td><td align="left">Lig@O11</td><td align="char" char=".">2.61</td><td align="char" char=".">69.84</td></tr><tr><td align="left">Glu811@O</td><td align="left">Lig@O10</td><td align="char" char=".">2.76</td><td align="char" char=".">58.43</td></tr><tr><td align="left">Thr556@O</td><td align="left">Lig@O3</td><td align="char" char=".">2.72</td><td align="char" char=".">56.95</td></tr><tr><td align="left">Lig@O14</td><td align="left">Arg836@NH2</td><td align="char" char=".">2.83</td><td align="char" char=".">52.66</td></tr><tr><td align="left">Lig@O14</td><td align="left">Arg836@NE</td><td align="char" char=".">2.86</td><td align="char" char=".">48.70</td></tr><tr><td align="left">Asp761@OD2</td><td align="left">Lig@O20</td><td align="char" char=".">2.62</td><td align="char" char=".">44.51</td></tr><tr><td colspan="4" align="center">RdRp/TF2b</td></tr><tr><td align="left">Pro832@O</td><td align="left">Lig@O8</td><td align="char" char=".">2.77</td><td align="char" char=".">26.31</td></tr><tr><td align="left">Lig@O11</td><td align="left">Tyr877@OH</td><td align="char" char=".">2.75</td><td align="char" char=".">24.39</td></tr><tr><td align="left">Glu811@OE1</td><td align="left">Lig@O7</td><td align="char" char=".">2.65</td><td align="char" char=".">22.45</td></tr><tr><td align="left">Glu811@OE2</td><td align="left">Lig@O7</td><td align="char" char=".">2.65</td><td align="char" char=".">18.89</td></tr><tr><td align="left">Asp833@OD2</td><td align="left">Lig@O8</td><td align="char" char=".">2.65</td><td align="char" char=".">12.01</td></tr><tr><td align="left">Asn874@OD1</td><td align="left">Lig@O11</td><td align="char" char=".">2.68</td><td align="char" char=".">8.58</td></tr><tr><td colspan="4" align="center">RdRp<bold>/</bold>TF2a</td></tr><tr><td align="left">Asp618@OD1</td><td align="left">Lig@O10</td><td align="char" char=".">2.59</td><td align="char" char=".">38.68</td></tr><tr><td align="left">Asp618@OD1</td><td align="left">Lig@O11</td><td align="char" char=".">2.62</td><td align="char" char=".">38.38</td></tr><tr><td align="left">Asp760@O</td><td align="left">Lig@O11</td><td align="char" char=".">2.70</td><td align="char" char=".">20.83</td></tr><tr><td align="left">Asp618@OD2</td><td align="left">Lig@O11</td><td align="char" char=".">2.62</td><td align="char" char=".">16.59</td></tr><tr><td align="left">Asp618@OD2</td><td align="left">Lig@O10</td><td align="char" char=".">2.58</td><td align="char" char=".">16.49</td></tr><tr><td align="left">Asp618@OD1</td><td align="left">Lig@O15</td><td align="char" char=".">2.67</td><td align="char" char=".">16.37</td></tr></tbody></table></table-wrap><p>Finally, we supplemented the above results by analyzing the final conformation of each production simulation with the help of 2D LigPlot<sup>+</sup> software, and different h-bonds and hydrophobic interactions were shown in <xref ref-type="fig" rid="F0007">Figure 7</xref>. Hydrogen bonds are depicted in green dotted lines, while red semicircle residues are involved in hydrophobic interactions. For the RdRp/remdesivir complex, <xref ref-type="fig" rid="F0007">Figure 7(A)</xref> displayed nine hydrophobic interactions with Lys545, Ala547, Ser549, Arg553, Val557, Asp684, Ser759, Ser814, and Arg836. This large number of interactions account for the high stability and good binding affinity of remdesivir to RdRp. EGCG formed hydrophobic interactions with Lys551, Ala554, Arg553, Arg624, Pro620, (<xref ref-type="fig" rid="F0007">Figure 7(B)</xref>). In the case of TF3, eight hydrophobic interactions with His439, Ile548, Ser814, Phe812, Val557, Ser549, Tyr619 and Arg555 were formed as revealed by <xref ref-type="fig" rid="F0007">Figure 7(C)</xref>. <xref ref-type="fig" rid="F0007">Figure 7(D)</xref> shows that seven hydrophobic interactions with Asp833, His816, Pro832, Gln815, His872, His810 and Ser434 were formed for RdRp/TF2b. Finally, <xref ref-type="fig" rid="F0007">Figure 7(E)</xref> shows that RdRp/TF2a formed hydrophobic interactions with Arg555, Ala554 and Lys551. Overall, TF3 has a higher binding affinity toward RdRp compared to the other polyphenols due to a larger number of stable hydrogen bonds and hydrophobic interactions.</p><fig id="F0007" orientation="portrait" position="float"><label>Figure 7.</label><caption><p>The RdRp-ligands interaction profile for <bold>(A)</bold> RdRp/remdesivir, <bold>(B)</bold> RdRp/EGCG, <bold>(C)</bold> RdRp/TF3, <bold>(D)</bold> RdRp/TF2b and <bold>(E)</bold> RdRp/TF2a. The polyphenols and remdesivir are shown in balls and sticks. Hydrogen bonds are depicted in green dotted lines, and red semicircles residues are involved in hydrophobic interactions.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1796810_F0007_C"/></fig></sec></sec><sec id="S0003-S2003" disp-level="2"><label>3.3.</label><title>Prediction of the absorption, distribution, metabolism, excretion, and toxicity (ADMET) profile</title><p>In addition to testing the physiochemical efficiency of a given molecule to inhibit the target protein, other parameters such as absorption, distribution, metabolism, excretion, and toxicity (ADMET) of the inhibitor play a critical role on demonstrating the likelihood of success of a drug. Utilization of <italic>in-silico</italic> ADMET profiling, in combination with <italic>in&#x000a0;vivo</italic> and <italic>in&#x000a0;vitro</italic> predictions in the initial stage of the screening process, can significantly fasten the drug discovery process by minimizing the number of potential safety problems. Hence, we performed a detailed ADMET profiling to evaluate the drug likeliness of the four polyphenols: EGCG, TF2a, TF2b, TF3 that exhibited the highest score from the MD simulation and MM-PBSA study along with the positive control remdesivir.</p><p>Human colon adenocarcinoma-2 cell line (Caco2) permeability and human intestinal absorption (HIA) are key parameters to decide the total bioavailability of a drug. All the five compounds (EGCG, TF2a, TF2b, TF3, and remdesivir) showed comparatively low Caco2 permeability potential (&#x0003c;8&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6&#x02009;</sup>cm/s) and could be absorbed <italic>via</italic> the human intestine (Larregieu &#x00026; Benet, <xref rid="CIT0048" ref-type="bibr">2013</xref>). EGCG, TF2a, TF2b, TF3, and remdesivir were predicted to be substrates of permeability glycoprotein (P-glycoprotein), which is an efflux membrane protein. However, remdesivir was predicted as a P-glycoprotein I inhibitor, and EGCG and TF3 as a P-glycoprotein II inhibitor, whereas TF2a and TF2b as both P-glycoprotein I and II inhibitor. Hence, above mentioned five compounds could regulate the physiological functions of P-glycoprotein (see <xref rid="t0003" ref-type="table">Table S3</xref> in the <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07391102.2020.1796810">Supplementary Information</ext-link>).</p><p>The distribution of a drug is regulated by many parameters such as lipid-solubility, concentration in plasma and binding ability to plasma proteins, transport proteins, etc. The volume of distribution at steady-state (VDss) suggests that EGCG, TF2a, TF2b, TF3, and remdesivir had a lower theoretical dose required for uniform distribution in the plasma. Further, the degree of diffusion across the plasma membrane increases in the following order remdesivir&#x02009;&#x0003c;&#x02009;EGCG&#x02009;&#x0003c;&#x02009;TF2a&#x02009;&#x0003c;&#x02009;TF2b&#x02009;&#x0003c;&#x02009;TF3 (<xref rid="t0004" ref-type="table">Table S4</xref> in the <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07391102.2020.1796810">Supplementary Information</ext-link>) as measured by the fraction that is in the unbound state. The predictions through the distribution of the drugs <italic>via</italic> the central nervous system and blood-brain barrier suggest that these five compounds are poorly distributed to the brain and unable to penetrate the central nervous system. However, the medium level of the lipophilicity of the drugs suggests that they would have no negative impact on nervous system exposure.</p><p>Cytochromes P450 (CYP) isozymes play crucial roles in drug metabolism. It has been observed that TF2a, TF3, and remdesivir are a substrate of CYP3A4 and hence, can be efficiently metabolized by CYP3A4. On the other hand, EGCG is a CYP3A4 inhibitor (<xref rid="t0005" ref-type="table">Table S5</xref> in the <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07391102.2020.1796810">Supplementary Information</ext-link>). On a separate note, EGCG is predominantly metabolized in the small intestine and liver by the conjugate formation of glucuronide, methyl sulfates in the urine and plasma (Chow et&#x000a0;al. <xref rid="CIT0012" ref-type="bibr">2005</xref>).</p><p>Among the five compounds, TF2b and TF3 were predicted as the substrate of renal organic cation transporter-2 (Renal OCT2), as shown in <xref rid="t0006" ref-type="table">Table S6</xref> in the <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07391102.2020.1796810">Supplementary Information</ext-link>. While EGCG, TF2a, and remdesivir are possibly cleared through other available routes such as bile, breath, faces, and sweat. EGCG remains intact in the plasma and later excreted <italic>via</italic> bile and metabolized by colon microflora. It is also expected that all the compounds are absorbable <italic>via</italic> oral prescription.</p><p>We have also analyzed the toxicity profiles for EGCG, TF2a, TF2b, TF3 as well as remdesivir (see <xref rid="t0007" ref-type="table">Table 7</xref>). The toxicity prediction from the AMES test (<italic>Salmonella typhimurium</italic> reverse mutation assay) exhibited that all the compounds could be considered as non-mutagenic agents. High toxicity was observed for all the compounds in <italic>Tetrahymena pyriformis</italic>. EGCG, TF2a, TF2b, TF3, and remdesivir were shown to inhibit the human ether-a-go-go-related gene II (hERG II). However, Remdesivir has been shown to induce hepatotoxicity, whilst EGCG, TF2a, TF2b, TF3 are not likely to be associated with hepatotoxicity. The maximum recommended tolerated dose (MRTD) in human prediction shows that remdesivir violate MRTD whereas natural polyphenol EGCG, TF2a, TF2b, TF3 do not fall into this category. Remdesivir does not possess high acute toxicity whereas EGCG, TF2a, TF2b, and TF3 regarded as high acute toxic compound as it falls under minnow toxicity. Additionally, none of the compounds predicted to be associated with skin sensitization.</p><table-wrap id="t0007" orientation="portrait" position="float"><label>Table 7.</label><caption><p>Predicted toxicity profile of EGCG, TF3, TF2b, TF2a, and remdesivir.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">S. No.</th><th align="center">Compounds name</th><th align="center">Toxicity prediction</th><th align="center">&#x000a0;</th></tr><tr><th align="left">&#x000a0;</th><th align="center">&#x000a0;</th><th align="center">Properties</th><th align="center">Predicted values</th></tr></thead><tbody valign="top"><tr><td align="left">1</td><td align="left">EGCG</td><td align="left">AMES toxicity</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Maximum tolerated dose (Human)</td><td align="left">0.441 (log mg/kg/day)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">hERG I inhibitor</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">hERG II inhibitor</td><td align="left">Yes</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Oral rat acute toxicity (LD<sub>50</sub>)</td><td align="left">2.522 (mol/kg)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Oral rat chronic toxicity (LOAEL)</td><td align="left">3.065 (log mg/kg_bw/day)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Hepatotoxicity</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Skin sensitivity</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left"><italic toggle="yes">T. pyriformis</italic> toxicity</td><td align="left">0.285 (&#x000b5;g/L)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Minnow toxicity</td><td align="left">7.713 log mM</td></tr><tr><td align="left">2</td><td align="left">TF3</td><td align="left">AMES toxicity</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Maximum tolerated dose (Human)</td><td align="left">0.438 (log mg/kg/day)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">hERG I inhibitor</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">hERG II inhibitor</td><td align="left">Yes</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Oral rat acute toxicity (LD<sub>50</sub>)</td><td align="left">2.482 (mol/kg)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Oral rat chronic toxicity (LOAEL)</td><td align="left">7.443 (log mg/kg_bw/day)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Hepatotoxicity</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Skin sensitivity</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left"><italic toggle="yes">T. pyriformis</italic> toxicity</td><td align="left">0.285 (&#x000b5;g/L)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Minnow toxicity</td><td align="left">9.738 log mM</td></tr><tr><td align="left">3</td><td align="left">TF2b</td><td align="left">AMES toxicity</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Maximum tolerated dose (Human)</td><td align="left">0.438 (log mg/kg/day)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">hERG I inhibitor</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">hERG II inhibitor</td><td align="left">Yes</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Oral rat acute toxicity (LD<sub>50</sub>)</td><td align="left">2.482 (mol/kg)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Oral rat chronic toxicity (LOAEL)</td><td align="left">5.322 (log mg/kg_bw/day)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Hepatotoxicity</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Skin sensitivity</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left"><italic toggle="yes">T. pyriformis</italic> toxicity</td><td align="left">0.285 (&#x000b5;g/L)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Minnow toxicity</td><td align="left">8.685 log mM</td></tr><tr><td align="left">4</td><td align="left">TF2a</td><td align="left">AMES toxicity</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Maximum tolerated dose (Human)</td><td align="left">0.439 (log mg/kg/day)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">hERG I inhibitor</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">hERG II inhibitor</td><td align="left">Yes</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Oral rat acute toxicity (LD<sub>50</sub>)</td><td align="left">2.484 (mol/kg)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Oral rat chronic toxicity (LOAEL)</td><td align="left">5.035 (log mg/kg_bw/day)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Hepatotoxicity</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Skin sensitivity</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left"><italic toggle="yes">T. pyriformis</italic> toxicity</td><td align="left">0.285 (&#x000b5;g/L)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Minnow toxicity</td><td align="left">4.898 log mM</td></tr><tr><td align="left">5</td><td align="left">Remdesivir</td><td align="left">AMES toxicity</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Maximum tolerated dose (Human)</td><td align="left">0.15 (log mg/kg/day)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">hERG I inhibitor</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">hERG II inhibitor</td><td align="left">Yes</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Oral rat acute toxicity (LD<sub>50</sub>)</td><td align="left">2.043 (mol/kg)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Oral rat chronic toxicity (LOAEL)</td><td align="left">1.639 (log mg/kg_bw/day)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Hepatotoxicity</td><td align="left">Yes</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Skin sensitivity</td><td align="left">No</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left"><italic toggle="yes">T. pyriformis</italic> toxicity</td><td align="left">0.285 (&#x000b5;g/L)</td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">Minnow toxicity</td><td align="left">0.291 log mM</td></tr></tbody></table></table-wrap></sec><sec id="S0003-S2004" disp-level="2"><label>3.4.</label><title>Identification of target class for natural polyphenol via target prediction studies</title><p>The polyphenolic structural motif of dietary polyphenols allows them to serve as excellent hydrogen bond donors which in turn help them to strongly interact with various biomacromolecules such as proteins. This interaction is a critical step in the regulatory role of polyphenols on various key proteins involved in cellular physiology. The majority, if not all, of the beneficial effect of polyphenols, can be explained via the functional consequence of proteins it interacts with. Molecular target studies help us to predict therapeutic protein targets for a given small molecule. Herein, we analyzed the predicted interacting proteins/enzymes for EGCG, TF2a, TF2b, TF3, and remdesivir. This study is particularly important in the current context as we think that these polyphenols could target RdRp, an important enzyme that catalyzes the RNA replication in the SARS-CoV-2. Notably, the molecular target analysis suggests that all four polyphenols possess excellent properties of druggability, and they interact with a diverse class of proteins/enzymes. The top 25 target classes of EGCG, TF2a, TF2b, TF3, and remdesivir are represented in the pie-chart, as shown in <xref ref-type="fig" rid="F0008">Figure 8</xref>. The detailed output table with the target, common name, UniProt ID, ChEMBL ID, target class, probability, and known actives in 2D/3D are listed in Tables S7&#x02013;S11 in the <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/07391102.2020.1796810">Supplementary Information</ext-link>.</p><fig id="F0008" orientation="portrait" position="float"><label>Figure 8.</label><caption><p>Molecular target predictions for <bold>(A)</bold> EGCG, <bold>(B)</bold> TF2a, <bold>(C)</bold> TF2b <bold>(D)</bold> TF3, and <bold>(E)</bold> remdesivir obtained from swiss target prediction report. The frequency of the target classes (top 25) is depicted in the pie chart.</p></caption><graphic content-type="color" xlink:href="TBSD_A_1796810_F0008_C"/></fig></sec></sec><sec id="S0004" disp-level="1"><label>4.</label><title>Conclusions</title><p>Keeping in mind that RdRp inhibitors play a crucial role to combat the SARS-CoV-2 infection, in this work, we performed a comprehensive molecular docking study with a library of hundred natural polyphenols with potential antiviral properties that may inhibit the SARS-CoV-2 RdRp and prevent the RNA replication. We shortlisted eight natural polyphenols having binding energy &#x02212;7.0&#x02009;kcal/mol or less for molecular dynamics simulation. Further, we performed 150&#x02009;ns molecular dynamics simulation of RdRp/EGCG, RdRp/TF1, RdRp/TF2a, RdRp/TF2b, RdRp/TF3, RdRp/hesperidin, RdRp/myricetin, RdRp/quercetagetin, along with RdRp/remdesivir complex and computed the binding energies by the molecular mechanics-Poisson-Boltzmann surface area (MM-PBSA) scheme from last 50&#x02009;ns trajectories. Our study suggests that the complex formation of the SARS-CoV-2 RdRp and eight natural polyphenols is favoured by the intermolecular van der Waals and electrostatic interactions as well as nonpolar solvation free energy. We have also investigated the hotspot residues controlling the receptor-ligand binding. Finally, molecular dynamics simulation and MM-PBSA study reveals that EGCG, TF2a, TF2b, and TF3 possess a better binding affinity than the control drug remdesivir against the SARS-CoV-2 RdRp. Further, we also looked at the ADME prediction, toxicity prediction, and target analysis to assess their druggability of the five compounds. The obtained results strongly suggest that EGCG, TF2a, TF2b, and TF3 have a stable binding affinity towards RdRp of the SARS-CoV-2 with favourable pharmacokinetic properties. These bioactive compounds exhibit broad ranges of therapeutic properties. Therefore, we believe that these four natural polyphenols can act as potential inhibitors for the SARS-CoV-2 RdRp. However, further <italic>in&#x000a0;vitro</italic> and <italic>in&#x000a0;vivo</italic> studies need to be carried out to validate their efficacy against SARS-CoV-2 infection.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SM0875"><caption><title>Supplemental Material</title></caption><media xlink:href="TBSD_A_1796810_SM0875.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><sec id="S0005" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>The authors declare that there is no conflict of interest.</p></sec><ref-list><title>References</title><ref id="CIT0001"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aanouz</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Belhassan</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>El Khatabi</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Lakhlifi</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>El Idrissi</surname><given-names>M.</given-names></name>, &#x00026; <name name-style="western"><surname>Bouachrine</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Moroccan medicinal plants as inhibitors of COVID-19: Computational investigations</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1758790</pub-id></mixed-citation></ref><ref id="CIT0002"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adeoye</surname><given-names>A. O.</given-names></name>, <name name-style="western"><surname>Oso</surname><given-names>B. J.</given-names></name>, <name name-style="western"><surname>Olaoye</surname><given-names>I. F.</given-names></name>, <name name-style="western"><surname>Tijjani</surname><given-names>H.</given-names></name>, &#x00026; <name name-style="western"><surname>Adebayo</surname><given-names>A. I.</given-names></name></person-group> (<year>2020</year>). <article-title>Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1765876</pub-id></mixed-citation></ref><ref id="CIT0003"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed-Belkacem</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Guichou</surname><given-names>J.-F.</given-names></name>, <name name-style="western"><surname>Brillet</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Ahnou</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Hernandez</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Pallier</surname><given-names>C.</given-names></name>, &#x00026; <name name-style="western"><surname>Pawlotsky</surname><given-names>J.-M.</given-names></name></person-group> (<year>2014</year>). <article-title>Inhibition of RNA binding to hepatitis C virus RNA-dependent RNA polymerase: A new mechanism for antiviral intervention</article-title>. <source><italic toggle="yes">Nucleic Acids Research</italic></source>, (<issue>14</issue>), <fpage>9399</fpage>&#x02013;<lpage>9409</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku632</pub-id><pub-id pub-id-type="pmid">25053847</pub-id></mixed-citation></ref><ref id="CIT0004"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berendsen</surname><given-names>H. J.</given-names></name>, <name name-style="western"><surname>Postma</surname><given-names>J. v.</given-names></name>, <name name-style="western"><surname>van Gunsteren</surname><given-names>W. F.</given-names></name>, <name name-style="western"><surname>DiNola</surname><given-names>A.</given-names></name>, &#x00026; <name name-style="western"><surname>Haak</surname><given-names>J.</given-names></name></person-group> (<year>1984</year>). <article-title>Molecular dynamics with coupling to an external bath</article-title>. <source><italic toggle="yes">The Journal of Chemical Physics</italic></source>, (<issue>8</issue>), <fpage>3684</fpage>&#x02013;<lpage>3690</lpage>. <pub-id pub-id-type="doi">10.1063/1.448118</pub-id></mixed-citation></ref><ref id="CIT0005"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berman</surname><given-names>H. M.</given-names></name>, <name name-style="western"><surname>Bhat</surname><given-names>T. N.</given-names></name>, <name name-style="western"><surname>Bourne</surname><given-names>P. E.</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Gilliland</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Weissig</surname><given-names>H.</given-names></name>, &#x00026; <name name-style="western"><surname>Westbrook</surname><given-names>J.</given-names></name></person-group> (<year>2000</year>). <article-title>The Protein Data Bank and the challenge of structural genomics</article-title>. <source><italic toggle="yes">Nucleic Acids Research</italic></source>, , <fpage>957</fpage>&#x02013;<lpage>959</lpage>.</mixed-citation></ref><ref id="CIT0006"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhardwaj</surname><given-names>V. K.</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Rajendran</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Purohit</surname><given-names>R.</given-names></name>, &#x00026; <name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Identification of bioactive molecules from Tea plant as SARS-CoV-2 main protease inhibitors</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1766572</pub-id></mixed-citation></ref><ref id="CIT0007"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boopathi</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Poma</surname><given-names>A. B.</given-names></name>, &#x00026; <name name-style="western"><surname>Kolandaivel</surname><given-names>P.</given-names></name></person-group> (<year>2020</year>). <article-title>Novel 2019 Coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1758788</pub-id></mixed-citation></ref><ref id="CIT0008"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borgio</surname><given-names>J. F.</given-names></name>, <name name-style="western"><surname>Alsuwat</surname><given-names>H. S.</given-names></name>, <name name-style="western"><surname>Al Otaibi</surname><given-names>W. M.</given-names></name>, <name name-style="western"><surname>Ibrahim</surname><given-names>A. M.</given-names></name>, <name name-style="western"><surname>Almandil</surname><given-names>N. B.</given-names></name>, <name name-style="western"><surname>Al Asoom</surname><given-names>L. I.</given-names></name>, <name name-style="western"><surname>Salahuddin</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Kamaraj</surname><given-names>B.</given-names></name>, &#x00026; <name name-style="western"><surname>AbdulAzeez</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2</article-title>. <source><italic toggle="yes">Archives of Medical Science: AMS</italic></source>, (<issue>3</issue>), <fpage>508</fpage>&#x02013;<lpage>518</lpage>. <pub-id pub-id-type="doi">10.5114/aoms.2020.94567</pub-id><pub-id pub-id-type="pmid">32399096</pub-id></mixed-citation></ref><ref id="CIT0009"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carneiro</surname><given-names>B. M.</given-names></name>, <name name-style="western"><surname>Batista</surname><given-names>M. N.</given-names></name>, <name name-style="western"><surname>Braga</surname><given-names>A. C. S.</given-names></name>, <name name-style="western"><surname>Nogueira</surname><given-names>M. L.</given-names></name>, &#x00026; <name name-style="western"><surname>Rahal</surname><given-names>P.</given-names></name></person-group> (<year>2016</year>). <article-title>The green tea molecule EGCG inhibits Zika virus entry</article-title>. <source><italic toggle="yes">Virology</italic></source>, , <fpage>215</fpage>&#x02013;<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2016.06.012</pub-id></mixed-citation></ref><ref id="CIT0010"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Case</surname><given-names>D. A.</given-names></name>, <name name-style="western"><surname>Ben-Shalom</surname><given-names>I. Y.</given-names></name>, <name name-style="western"><surname>Brozell</surname><given-names>S. R.</given-names></name>, <name name-style="western"><surname>Cerutti</surname><given-names>D. S.</given-names></name>, <name name-style="western"><surname>Cheatham</surname><given-names>T. E.</given-names><suffix>III</suffix></name>, <name name-style="western"><surname>Cruzeiro</surname><given-names>V. W. D.</given-names></name>, <name name-style="western"><surname>Darden</surname><given-names>T. A.</given-names></name>, <name name-style="western"><surname>Duke</surname><given-names>R. E.</given-names></name>, <name name-style="western"><surname>Ghoreishi</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Gilson</surname><given-names>M. K.</given-names></name>, <name name-style="western"><surname>Gohlke</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Goetz</surname><given-names>A. W.</given-names></name>, <name name-style="western"><surname>Greene</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Homeyer</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Izadi</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kovalenko</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Kurtzman</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>T. S.</given-names></name>, &#x02026; <name name-style="western"><surname>Kollman</surname><given-names>P. A.</given-names></name></person-group> (<year>2018</year>). <source><italic toggle="yes">AMBER 2018</italic></source>. <publisher-name>University of California</publisher-name>.</mixed-citation></ref><ref id="CIT0011"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J. F.</given-names></name>, <name name-style="western"><surname>Lau</surname><given-names>S. K.</given-names></name>, <name name-style="western"><surname>To</surname><given-names>K. K.</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>V. C.</given-names></name>, <name name-style="western"><surname>Woo</surname><given-names>P. C.</given-names></name>, &#x00026; <name name-style="western"><surname>Yuen</surname><given-names>K.-Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Middle East respiratory syndrome coronavirus: Another zoonotic betacoronavirus causing SARS-like disease</article-title>. <source><italic toggle="yes">Clinical Microbiology Reviews</italic></source>, (<issue>2</issue>), <fpage>465</fpage>&#x02013;<lpage>522</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.00102-14</pub-id><pub-id pub-id-type="pmid">25810418</pub-id></mixed-citation></ref><ref id="CIT0012"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>H. S.</given-names></name>, <name name-style="western"><surname>Hakim</surname><given-names>I. A.</given-names></name>, <name name-style="western"><surname>Vining</surname><given-names>D. R.</given-names></name>, <name name-style="western"><surname>Crowell</surname><given-names>J. A.</given-names></name>, <name name-style="western"><surname>Ranger-Moore</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Chew</surname><given-names>W. M.</given-names></name>, <name name-style="western"><surname>Celaya</surname><given-names>C. A.</given-names></name>, <name name-style="western"><surname>Rodney</surname><given-names>S. R.</given-names></name>, <name name-style="western"><surname>Hara</surname><given-names>Y.</given-names></name>, &#x00026; <name name-style="western"><surname>Alberts</surname><given-names>D. S.</given-names></name></person-group> (<year>2005</year>). <article-title>Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals</article-title>. <source><italic toggle="yes">Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</italic></source>, (<issue>12</issue>), <fpage>4627</fpage>&#x02013;<lpage>4633</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-2549</pub-id><pub-id pub-id-type="pmid">15958649</pub-id></mixed-citation></ref><ref id="CIT0013"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chowdhury</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Sahuc</surname><given-names>M.-E.</given-names></name>, <name name-style="western"><surname>Rouill&#x000e9;</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Rivi&#x000e8;re</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Bonneau</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Vandeputte</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Brodin</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Goswami</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Bandyopadhyay</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Dubuisson</surname><given-names>J.</given-names></name>, &#x00026; <name name-style="western"><surname>S&#x000e9;ron</surname><given-names>K.</given-names></name></person-group> (<year>2018</year>). <article-title>Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture</article-title>. <source><italic toggle="yes">PloS One</italic></source>, (<issue>11</issue>), <fpage>e0198226</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0198226</pub-id><pub-id pub-id-type="pmid">30485282</pub-id></mixed-citation></ref><ref id="CIT0014"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cory</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Passarelli</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Szeto</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Tamez</surname><given-names>M.</given-names></name>, &#x00026; <name name-style="western"><surname>Mattei</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <article-title>The role of polyphenols in human health and food systems: A mini-review</article-title>. <source><italic toggle="yes">Frontiers in Nutrition</italic></source>, , <fpage>87</fpage>
<pub-id pub-id-type="doi">10.3389/fnut.2018.00087</pub-id><pub-id pub-id-type="pmid">30298133</pub-id></mixed-citation></ref><ref id="CIT0015"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darden</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>York</surname><given-names>D.</given-names></name>, &#x00026; <name name-style="western"><surname>Pedersen</surname><given-names>L.</given-names></name></person-group> (<year>1993</year>). <article-title>Particle mesh Ewald: An N&#x022c5; log (N) method for Ewald sums in large systems</article-title>. <source><italic toggle="yes">The Journal of Chemical Physics</italic></source>, (<issue>12</issue>), <fpage>10089</fpage>&#x02013;<lpage>10092</lpage>. <pub-id pub-id-type="doi">10.1063/1.464397</pub-id></mixed-citation></ref><ref id="CIT0016"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elfiky</surname><given-names>A. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Zika virus: Novel guanosine derivatives revealed strong binding and possible inhibition of the polymerase</article-title>. <source><italic toggle="yes">Future Virology</italic></source>, (<issue>12</issue>), <fpage>721</fpage>&#x02013;<lpage>728</lpage>. <pub-id pub-id-type="doi">10.2217/fvl-2017-0081</pub-id></mixed-citation></ref><ref id="CIT0017"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elfiky</surname><given-names>A. A.</given-names></name></person-group> (<year>2019</year>). <article-title>Novel guanosine derivatives as anti-HCV NS5b polymerase: A QSAR and molecular docking Study</article-title>. <source><italic toggle="yes">Medicinal Chemistry</italic></source>, (<issue>2</issue>), <fpage>130</fpage>&#x02013;<lpage>137</lpage>. <pub-id pub-id-type="doi">10.2174/1573406414666181015152511</pub-id><pub-id pub-id-type="pmid">30324891</pub-id></mixed-citation></ref><ref id="CIT0018"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elfiky</surname><given-names>A. A.</given-names></name></person-group> (<year>2020a</year>). <article-title>Anti-HCV, nucleotide inhibitors, repurposing against COVID-19</article-title>. <source><italic toggle="yes">Life Sciences</italic></source>, , <fpage>117477</fpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2020.117477</pub-id><pub-id pub-id-type="pmid">32119961</pub-id></mixed-citation></ref><ref id="CIT0019"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elfiky</surname><given-names>A. A.</given-names></name></person-group> (<year>2020b</year>). <article-title>Natural products may interfere with SARS-CoV-2 attachment to the host cell</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1761881</pub-id></mixed-citation></ref><ref id="CIT0020"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elfiky</surname><given-names>A. A.</given-names></name></person-group> (<year>2020c</year>). <article-title>SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: An in silico perspective</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1761882</pub-id></mixed-citation></ref><ref id="CIT0021"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elfiky</surname><given-names>A. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Azzam</surname><given-names>E. B.</given-names></name></person-group> (<year>2020</year>). <article-title>Novel Guanosine Derivatives against MERS CoV polymerase: An in silico perspective</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1758789</pub-id></mixed-citation></ref><ref id="CIT0022"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmezayen</surname><given-names>A. D.</given-names></name>, <name name-style="western"><surname>Al-Obaidi</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>&#x0015e;ahin</surname><given-names>A. T.</given-names></name>, &#x00026; <name name-style="western"><surname>Yelek&#x000e7;i</surname><given-names>K.</given-names></name></person-group> (<year>2020</year>). <article-title>Drug repurposing for coronavirus (COVID-19): In silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1758791</pub-id></mixed-citation></ref><ref id="CIT0023"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enmozhi</surname><given-names>S. K.</given-names></name>, <name name-style="western"><surname>Raja</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Sebastine</surname><given-names>I.</given-names></name>, &#x00026; <name name-style="western"><surname>Joseph</surname><given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: An in silico approach</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1760136</pub-id></mixed-citation></ref><ref id="CIT0024"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganesan</surname><given-names>A.</given-names></name>, &#x00026; <name name-style="western"><surname>Barakat</surname><given-names>K.</given-names></name></person-group> (<year>2017</year>). <article-title>Applications of computer-aided approaches in the development of hepatitis C antiviral agents</article-title>. <source><italic toggle="yes">Expert Opinion on Drug Discovery</italic></source>, (<issue>4</issue>), <fpage>407</fpage>&#x02013;<lpage>425</lpage>. <pub-id pub-id-type="doi">10.1080/17460441.2017.1291628</pub-id><pub-id pub-id-type="pmid">28164720</pub-id></mixed-citation></ref><ref id="CIT0025"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gfeller</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Grosdidier</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Wirth</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Daina</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Michielin</surname><given-names>O.</given-names></name>, &#x00026; <name name-style="western"><surname>Zoete</surname><given-names>V.</given-names></name></person-group> (<year>2014</year>). <article-title>SwissTargetPrediction: A web server for target prediction of bioactive small molecules</article-title>. <source><italic toggle="yes">Nucleic Acids Research</italic></source>, (<issue>Web Server issue</issue>), <fpage>W32</fpage>&#x02013;<lpage>W38</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gku293</pub-id><pub-id pub-id-type="pmid">24792161</pub-id></mixed-citation></ref><ref id="CIT0026"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gohlke</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Kiel</surname><given-names>C.</given-names></name>, &#x00026; <name name-style="western"><surname>Case</surname><given-names>D. A.</given-names></name></person-group> (<year>2003</year>). <article-title>Insights into protein&#x02013;protein binding by binding free energy calculation and free energy decomposition for the Ras&#x02013;Raf and Ras&#x02013;RalGDS complexes</article-title>. <source><italic toggle="yes">Journal of Molecular Biology</italic></source>, (<issue>4</issue>), <fpage>891</fpage>&#x02013;<lpage>913</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-2836(03)00610-7</pub-id></mixed-citation></ref><ref id="CIT0027"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hendaus</surname><given-names>M. A.</given-names></name></person-group> (<year>2020</year>). <article-title>Remdesivir in the treatment of Coronavirus Disease 2019 (COVID-19): A simplified summary</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1767691</pub-id></mixed-citation></ref><ref id="CIT0028"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>H.-Y.</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>M.-L.</given-names></name>, <name name-style="western"><surname>Weng</surname><given-names>S.-F.</given-names></name>, <name name-style="western"><surname>Leu</surname><given-names>Y.-L.</given-names></name>, &#x00026; <name name-style="western"><surname>Chiu</surname><given-names>D. T.-Y.</given-names></name></person-group> (<year>2009</year>). <article-title>Antiviral effect of epigallocatechin gallate on enterovirus 71</article-title>. <source><italic toggle="yes">Journal of Agricultural and Food Chemistry</italic></source>, (<issue>14</issue>), <fpage>6140</fpage>&#x02013;<lpage>6147</lpage>. <pub-id pub-id-type="doi">10.1021/jf901128u</pub-id><pub-id pub-id-type="pmid">19537794</pub-id></mixed-citation></ref><ref id="CIT0029"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibrahim</surname><given-names>I. M.</given-names></name>, <name name-style="western"><surname>Abdelmalek</surname><given-names>D. H.</given-names></name>, <name name-style="western"><surname>Elshahat</surname><given-names>M. E.</given-names></name>, &#x00026; <name name-style="western"><surname>Elfiky</surname><given-names>A. A.</given-names></name></person-group> (<year>2020</year>). <article-title>COVID-19 spike-host cell receptor GRP78 binding site prediction</article-title>. <source><italic toggle="yes">The Journal of Infection</italic></source>, (<issue>5</issue>), <fpage>554</fpage>&#x02013;<lpage>562</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2020.02.026</pub-id><pub-id pub-id-type="pmid">32169481</pub-id></mixed-citation></ref><ref id="CIT0030"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Parves</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Paul</surname><given-names>A. S.</given-names></name>, <name name-style="western"><surname>Uddin</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Rahman</surname><given-names>M. S.</given-names></name>, <name name-style="western"><surname>Mamun</surname><given-names>A. A.</given-names></name>, <name name-style="western"><surname>Hossain</surname><given-names>M. N.</given-names></name>, <name name-style="western"><surname>Ali</surname><given-names>M. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Halim</surname><given-names>M. A.</given-names></name></person-group> (<year>2020</year>). <article-title>A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1761883</pub-id></mixed-citation></ref><ref id="CIT0031"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jakalian</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Jack</surname><given-names>D. B.</given-names></name>, &#x00026; <name name-style="western"><surname>Bayly</surname><given-names>C. I.</given-names></name></person-group> (<year>2002</year>). <article-title>Fast, efficient generation of high&#x02010;quality atomic charges. AM1&#x02010;BCC model: II. Parameterization and validation</article-title>. <source><italic toggle="yes">Journal of Computational Chemistry</italic></source>, (<issue>16</issue>), <fpage>1623</fpage>&#x02013;<lpage>1641</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.10128</pub-id><pub-id pub-id-type="pmid">12395429</pub-id></mixed-citation></ref><ref id="CIT0032"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>H.</given-names></name>, &#x00026; <name name-style="western"><surname>Gong</surname><given-names>P.</given-names></name></person-group> (<year>2019</year>). <article-title>A structure-function diversity survey of the RNA-dependent RNA polymerases from the positive-strand RNA viruses</article-title>. <source><italic toggle="yes">Frontiers in Microbiology</italic></source>, , <fpage>1945</fpage>
<pub-id pub-id-type="doi">10.3389/fmicb.2019.01945</pub-id><pub-id pub-id-type="pmid">31507560</pub-id></mixed-citation></ref><ref id="CIT0033"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jonniya</surname><given-names>N. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Kar</surname><given-names>P.</given-names></name></person-group> (<year>2020</year>). <article-title>Investigating specificity of the anti-hypertensive inhibitor WNK463 against With-No-Lysine kinase family isoforms via multiscale simulations</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure &#x00026; Dynamics</italic></source>, (<issue>5</issue>), <fpage>1306</fpage>&#x02013;<lpage>1321</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2019.1602079</pub-id><pub-id pub-id-type="pmid">31017050</pub-id></mixed-citation></ref><ref id="CIT0034"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jonniya</surname><given-names>N. A.</given-names></name>, <name name-style="western"><surname>Sk</surname><given-names>M. F.</given-names></name>, &#x00026; <name name-style="western"><surname>Kar</surname><given-names>P.</given-names></name></person-group> (<year>2019</year>). <article-title>Investigating phosphorylation-induced conformational changes in WNK1 kinase by molecular dynamics simulations</article-title>. <source><italic toggle="yes">ACS Omega</italic></source>, (<issue>17</issue>), <fpage>17404</fpage>&#x02013;<lpage>17416</lpage>. <pub-id pub-id-type="doi">10.1021/acsomega.9b02187</pub-id><pub-id pub-id-type="pmid">31656913</pub-id></mixed-citation></ref><ref id="CIT0035"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kar</surname><given-names>P.</given-names></name>, &#x00026; <name name-style="western"><surname>Knecht</surname><given-names>V.</given-names></name></person-group> (<year>2012</year>a). <article-title>Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir</article-title>. <source><italic toggle="yes">Journal of Computer-Aided Molecular Design</italic></source>, (<issue>2</issue>), <fpage>215</fpage>&#x02013;<lpage>232</lpage>. <pub-id pub-id-type="doi">10.1007/s10822-012-9550-5</pub-id><pub-id pub-id-type="pmid">22350569</pub-id></mixed-citation></ref><ref id="CIT0036"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kar</surname><given-names>P.</given-names></name>, &#x00026; <name name-style="western"><surname>Knecht</surname><given-names>V.</given-names></name></person-group> (<year>2012</year>b). <article-title>Energetics of mutation-induced changes in potency of lersivirine against HIV-1 reverse transcriptase</article-title>. <source><italic toggle="yes">The Journal of Physical Chemistry B</italic></source>, (<issue>22</issue>), <fpage>6269</fpage>&#x02013;<lpage>6278</lpage>. <pub-id pub-id-type="doi">10.1021/jp300818c</pub-id><pub-id pub-id-type="pmid">22574920</pub-id></mixed-citation></ref><ref id="CIT0037"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kar</surname><given-names>P.</given-names></name>, &#x00026; <name name-style="western"><surname>Knecht</surname><given-names>V.</given-names></name></person-group> (<year>2012</year>c). <article-title>Mutation-induced loop opening and energetics for binding of tamiflu to influenza N8 neuraminidase</article-title>. <source><italic toggle="yes">The Journal of Physical Chemistry B</italic></source>, (<issue>21</issue>), <fpage>6137</fpage>&#x02013;<lpage>6149</lpage>. <pub-id pub-id-type="doi">10.1021/jp3022612</pub-id><pub-id pub-id-type="pmid">22553951</pub-id></mixed-citation></ref><ref id="CIT0038"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kar</surname><given-names>P.</given-names></name>, &#x00026; <name name-style="western"><surname>Knecht</surname><given-names>V.</given-names></name></person-group> (<year>2012</year>d). <article-title>Origin of decrease in potency of darunavir and two related antiviral inhibitors against HIV-2 compared to HIV-1 protease</article-title>. <source><italic toggle="yes">The Journal of Physical Chemistry B</italic></source>, (<issue>8</issue>), <fpage>2605</fpage>&#x02013;<lpage>2614</lpage>. <pub-id pub-id-type="doi">10.1021/jp211768n</pub-id><pub-id pub-id-type="pmid">22280246</pub-id></mixed-citation></ref><ref id="CIT0039"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kar</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Lipowsky</surname><given-names>R.</given-names></name>, &#x00026; <name name-style="western"><surname>Knecht</surname><given-names>V.</given-names></name></person-group> (<year>2011</year>). <article-title>Importance of polar solvation for cross-reactivity of antibody and its variants with steroids</article-title>. <source><italic toggle="yes">The Journal of Physical Chemistry B</italic></source>, (<issue>23</issue>), <fpage>7661</fpage>&#x02013;<lpage>7669</lpage>. <pub-id pub-id-type="doi">10.1021/jp201538t</pub-id><pub-id pub-id-type="pmid">21595427</pub-id></mixed-citation></ref><ref id="CIT0040"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kar</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Lipowsky</surname><given-names>R.</given-names></name>, &#x00026; <name name-style="western"><surname>Knecht</surname><given-names>V.</given-names></name></person-group> (<year>2013</year>). <article-title>Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease</article-title>. <source><italic toggle="yes">The Journal of Physical Chemistry B</italic></source>, (<issue>19</issue>), <fpage>5793</fpage>&#x02013;<lpage>5805</lpage>. <pub-id pub-id-type="doi">10.1021/jp3085292</pub-id><pub-id pub-id-type="pmid">23614718</pub-id></mixed-citation></ref><ref id="CIT0041"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kar</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Seel</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Hansmann</surname><given-names>U. H.</given-names></name>, &#x00026; <name name-style="western"><surname>H&#x000f6;finger</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>). <article-title>Dispersion terms and analysis of size- and charge dependence in an enhanced Poisson-Boltzmann approach</article-title>. <source><italic toggle="yes">The Journal of Physical Chemistry B</italic></source>, (<issue>30</issue>), <fpage>8910</fpage>&#x02013;<lpage>8918</lpage>. <pub-id pub-id-type="doi">10.1021/jp072302u</pub-id><pub-id pub-id-type="pmid">17628098</pub-id></mixed-citation></ref><ref id="CIT0042"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kar</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Hansmann</surname><given-names>U. H.</given-names></name>, &#x00026; <name name-style="western"><surname>H&#x000f6;finger</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>). <article-title>Systematic study of the boundary composition in Poisson Boltzmann calculations</article-title>. <source><italic toggle="yes">Journal of Computational Chemistry</italic></source>, (<issue>16</issue>), <fpage>2538</fpage>&#x02013;<lpage>2544</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.20698</pub-id><pub-id pub-id-type="pmid">17503456</pub-id></mixed-citation></ref><ref id="CIT0043"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>M. T.</given-names></name>, <name name-style="western"><surname>Ali</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Irfan</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Zeb</surname><given-names>M. T.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.-J.</given-names></name>, <name name-style="western"><surname>Chinnasamy</surname><given-names>S.</given-names></name>, &#x00026; <name name-style="western"><surname>Wei</surname><given-names>D.-Q.</given-names></name></person-group> (<year>2020</year>). <article-title>Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2. A molecular dynamic study</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure and Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1769733</pub-id></mixed-citation></ref><ref id="CIT0044"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Gindulyte</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Shoemaker</surname><given-names>B. A.</given-names></name>, <name name-style="western"><surname>Thiessen</surname><given-names>P. A.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Zaslavsky</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name>, &#x00026; <name name-style="western"><surname>Bolton</surname><given-names>E. E.</given-names></name></person-group> (<year>2019</year>). <article-title>PubChem 2019 update: Improved access to chemical data</article-title>. <source><italic toggle="yes">Nucleic Acids Research</italic></source>, (<issue>D1</issue>), <fpage>D1102</fpage>&#x02013;<lpage>D1109</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1033</pub-id><pub-id pub-id-type="pmid">30371825</pub-id></mixed-citation></ref><ref id="CIT0045"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kollman</surname><given-names>P. A.</given-names></name>, <name name-style="western"><surname>Massova</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Reyes</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Kuhn</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Huo</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Chong</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Donini</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Cieplak</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Srinivasan</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Case</surname><given-names>D. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Cheatham</surname><given-names>T. E.</given-names></name></person-group> (<year>2000</year>). <article-title>Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models</article-title>. <source><italic toggle="yes">Accounts of Chemical Research</italic></source>, (<issue>12</issue>), <fpage>889</fpage>&#x02013;<lpage>897</lpage>. <pub-id pub-id-type="doi">10.1021/ar000033j</pub-id><pub-id pub-id-type="pmid">11123888</pub-id></mixed-citation></ref><ref id="CIT0046"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kr&#x000e4;utler</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>van Gunsteren</surname><given-names>W. F.</given-names></name>, &#x00026; <name name-style="western"><surname>H&#x000fc;nenberger</surname><given-names>P. H.</given-names></name></person-group> (<year>2001</year>). <article-title>A fast SHAKE algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations</article-title>. <source><italic toggle="yes">Journal of Computational Chemistry</italic></source>, (<issue>5</issue>), <fpage>501</fpage>&#x02013;<lpage>508</lpage>. <pub-id pub-id-type="doi">10.1002/1096-987X(20010415)22:5&#x0003c;501::AID-JCC1021&#x0003e;3.0.CO;2-V</pub-id></mixed-citation></ref><ref id="CIT0047"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuzuhara</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Iwai</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Takahashi</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Hatakeyama</surname><given-names>D.</given-names></name>, &#x00026; <name name-style="western"><surname>Echigo</surname><given-names>N.</given-names></name></person-group> (<year>2009</year>). <article-title>Green tea catechins inhibit the endonuclease activity of influenza A virus RNA polymerase</article-title>. <source><italic toggle="yes">PLoS Currents</italic></source>, , <fpage>RRN1052</fpage>
<pub-id pub-id-type="doi">10.1371/currents.RRN1052</pub-id><pub-id pub-id-type="pmid">20025206</pub-id></mixed-citation></ref><ref id="CIT0048"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larregieu</surname><given-names>C. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Benet</surname><given-names>L. Z.</given-names></name></person-group> (<year>2013</year>). <article-title>Drug discovery and regulatory considerations for improving in silico and in&#x000a0;vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements</article-title>. <source><italic toggle="yes">The AAPS Journal</italic></source>, (<issue>2</issue>), <fpage>483</fpage>&#x02013;<lpage>497</lpage>. <pub-id pub-id-type="doi">10.1208/s12248-013-9456-8</pub-id><pub-id pub-id-type="pmid">23344793</pub-id></mixed-citation></ref><ref id="CIT0049"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L.-T.</given-names></name>, <name name-style="western"><surname>Hsu</surname><given-names>W.-C.</given-names></name>, &#x00026; <name name-style="western"><surname>Lin</surname><given-names>C.-C.</given-names></name></person-group> (<year>2014</year>). <article-title>Antiviral natural products and herbal medicines</article-title>. <source><italic toggle="yes">Journal of Traditional and Complementary Medicine</italic></source>, (<issue>1</issue>), <fpage>24</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.4103/2225-4110.124335</pub-id><pub-id pub-id-type="pmid">24872930</pub-id></mixed-citation></ref><ref id="CIT0050"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loncharich</surname><given-names>R. J.</given-names></name>, <name name-style="western"><surname>Brooks</surname><given-names>B. R.</given-names></name>, &#x00026; <name name-style="western"><surname>Pastor</surname><given-names>R. W.</given-names></name></person-group> (<year>1992</year>). <article-title>Langevin dynamics of peptides: The frictional dependence of isomerization rates of N-acetylalanyl-N'-methylamide</article-title>. <source><italic toggle="yes">Biopolymers</italic></source>, (<issue>5</issue>), <fpage>523</fpage>&#x02013;<lpage>535</lpage>. <pub-id pub-id-type="doi">10.1002/bip.360320508</pub-id><pub-id pub-id-type="pmid">1515543</pub-id></mixed-citation></ref><ref id="CIT0051"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maier</surname><given-names>J. A.</given-names></name>, <name name-style="western"><surname>Martinez</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Kasavajhala</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Wickstrom</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Hauser</surname><given-names>K. E.</given-names></name>, &#x00026; <name name-style="western"><surname>Simmerling</surname><given-names>C.</given-names></name></person-group> (<year>2015</year>). <article-title>ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB</article-title>. <source><italic toggle="yes">Journal of Chemical Theory and Computation</italic></source>, (<issue>8</issue>), <fpage>3696</fpage>&#x02013;<lpage>3713</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jctc.5b00255</pub-id><pub-id pub-id-type="pmid">26574453</pub-id></mixed-citation></ref><ref id="CIT0052"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>Y. J.</given-names></name>, &#x00026; <name name-style="western"><surname>Morris</surname><given-names>M. E.</given-names></name></person-group> (<year>2007</year>). <article-title>Pharmacokinetics and bioavailability of the bioflavonoid biochanin A: Effects of quercetin and EGCG on biochanin A disposition in rats</article-title>. <source><italic toggle="yes">Molecular Pharmaceutics</italic></source>, (<issue>6</issue>), <fpage>865</fpage>&#x02013;<lpage>872</lpage>. <pub-id pub-id-type="doi">10.1021/mp7000928</pub-id><pub-id pub-id-type="pmid">17970592</pub-id></mixed-citation></ref><ref id="CIT0053"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>G. M.</given-names></name>, <name name-style="western"><surname>Huey</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Lindstrom</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Sanner</surname><given-names>M. F.</given-names></name>, <name name-style="western"><surname>Belew</surname><given-names>R. K.</given-names></name>, <name name-style="western"><surname>Goodsell</surname><given-names>D. S.</given-names></name>, &#x00026; <name name-style="western"><surname>Olson</surname><given-names>A. J.</given-names></name></person-group> (<year>2009</year>). <article-title>AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility</article-title>. <source><italic toggle="yes">Journal of Computational Chemistry</italic></source>, (<issue>16</issue>), <fpage>2785</fpage>&#x02013;<lpage>2791</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id><pub-id pub-id-type="pmid">19399780</pub-id></mixed-citation></ref><ref id="CIT0054"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muralidharan</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Sakthivel</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Velmurugan</surname><given-names>D.</given-names></name>, &#x00026; <name name-style="western"><surname>Gromiha</surname><given-names>M. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1752802</pub-id></mixed-citation></ref><ref id="CIT0055"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pettersen</surname><given-names>E. F.</given-names></name>, <name name-style="western"><surname>Goddard</surname><given-names>T. D.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>C. C.</given-names></name>, <name name-style="western"><surname>Couch</surname><given-names>G. S.</given-names></name>, <name name-style="western"><surname>Greenblatt</surname><given-names>D. M.</given-names></name>, <name name-style="western"><surname>Meng</surname><given-names>E. C.</given-names></name>, &#x00026; <name name-style="western"><surname>Ferrin</surname><given-names>T. E.</given-names></name></person-group> (<year>2004</year>). <article-title>UCSF Chimera-a visualization system for exploratory research and analysis</article-title>. <source><italic toggle="yes">Journal of Computational Chemistry</italic></source>, (<issue>13</issue>), <fpage>1605</fpage>&#x02013;<lpage>1612</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><pub-id pub-id-type="pmid">15264254</pub-id></mixed-citation></ref><ref id="CIT0056"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pires</surname><given-names>D. E.</given-names></name>, <name name-style="western"><surname>Blundell</surname><given-names>T. L.</given-names></name>, &#x00026; <name name-style="western"><surname>Ascher</surname><given-names>D. B.</given-names></name></person-group> (<year>2015</year>). <article-title>pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures</article-title>. <source><italic toggle="yes">Journal of Medicinal Chemistry</italic></source>, (<issue>9</issue>), <fpage>4066</fpage>&#x02013;<lpage>4072</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00104</pub-id><pub-id pub-id-type="pmid">25860834</pub-id></mixed-citation></ref><ref id="CIT0057"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Price</surname><given-names>D. J.</given-names></name>, &#x00026; <name name-style="western"><surname>Brooks III</surname><given-names>C. L.</given-names></name></person-group> (<year>2004</year>). <article-title>A modified TIP3P water potential for simulation with Ewald summation</article-title>. <source><italic toggle="yes">The Journal of Chemical Physics</italic></source>, (<issue>20</issue>), <fpage>10096</fpage>&#x02013;<lpage>10103</lpage>. <pub-id pub-id-type="doi">10.1063/1.1808117</pub-id><pub-id pub-id-type="pmid">15549884</pub-id></mixed-citation></ref><ref id="CIT0058"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Randall</surname><given-names>R. E.</given-names></name>, &#x00026; <name name-style="western"><surname>Goodbourn</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>Interferons and viruses: An interplay between induction, signalling, antiviral responses and virus countermeasures</article-title>. <source><italic toggle="yes">The Journal of General Virology</italic></source>, (<issue>Pt 1</issue>), <fpage>1</fpage>&#x02013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.83391-0</pub-id><pub-id pub-id-type="pmid">18089727</pub-id></mixed-citation></ref><ref id="CIT0059"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roe</surname><given-names>D. R.</given-names></name>, &#x00026; <name name-style="western"><surname>Cheatham III</surname><given-names>T. E.</given-names></name></person-group> (<year>2013</year>). <article-title>PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data</article-title>. <source><italic toggle="yes">Journal of Chemical Theory and Computation</italic></source>, (<issue>7</issue>), <fpage>3084</fpage>&#x02013;<lpage>3095</lpage>. <pub-id pub-id-type="doi">10.1021/ct400341p</pub-id><pub-id pub-id-type="pmid">26583988</pub-id></mixed-citation></ref><ref id="CIT0060"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Ghosh</surname><given-names>B.</given-names></name>, &#x00026; <name name-style="western"><surname>Kar</surname><given-names>P.</given-names></name></person-group> (<year>2020</year>). <article-title>Investigating conformational dynamics of Lewis Y oligosaccharides and elucidating blood group dependency of cholera using molecular dynamics</article-title>. <source><italic toggle="yes">ACS Omega</italic></source>, (<issue>8</issue>), <fpage>3932</fpage>&#x02013;<lpage>3942</lpage>. <pub-id pub-id-type="doi">10.1021/acsomega.9b03398</pub-id><pub-id pub-id-type="pmid">32149220</pub-id></mixed-citation></ref><ref id="CIT0061"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinha</surname><given-names>S. K.</given-names></name>, <name name-style="western"><surname>Shakya</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Prasad</surname><given-names>S. K.</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Gurav</surname><given-names>N. S.</given-names></name>, <name name-style="western"><surname>Prasad</surname><given-names>R. S.</given-names></name>, &#x00026; <name name-style="western"><surname>Gurav</surname><given-names>S. S.</given-names></name></person-group> (<year>2020</year>). <article-title>An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1762741</pub-id></mixed-citation></ref><ref id="CIT0062"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sk</surname><given-names>M. F.</given-names></name>, <name name-style="western"><surname>Roy</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Jonniya</surname><given-names>N. A.</given-names></name>, <name name-style="western"><surname>Poddar</surname><given-names>S.</given-names></name>, &#x00026; <name name-style="western"><surname>Kar</surname><given-names>P.</given-names></name></person-group> (<year>2020</year>). <article-title>Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2 main protease by using molecular dynamics simulations and free energy calculations</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.07392020.01768149</pub-id></mixed-citation></ref><ref id="CIT0063"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sk</surname><given-names>M. F.</given-names></name>, <name name-style="western"><surname>Roy</surname><given-names>R.</given-names></name>, &#x00026; <name name-style="western"><surname>Kar</surname><given-names>P.</given-names></name></person-group> (<year>2020</year>). <article-title>Exploring the potency of currently used drugs against HIV-1 protease of subtype D variant by using multiscale simulations</article-title>. <source><italic toggle="yes">Journal of Biomolecular Structure Dynamics</italic></source>. <pub-id pub-id-type="doi">10.1080/07391102.07392020.01724196</pub-id></mixed-citation></ref><ref id="CIT0064"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>J.-M.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>K.-H.</given-names></name>, &#x00026; <name name-style="western"><surname>Seong</surname><given-names>B.-L.</given-names></name></person-group> (<year>2005</year>). <article-title>Antiviral effect of catechins in green tea on influenza virus</article-title>. <source><italic toggle="yes">Antiviral Research</italic></source>, (<issue>2</issue>), <fpage>66</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2005.06.010</pub-id><pub-id pub-id-type="pmid">16137775</pub-id></mixed-citation></ref><ref id="CIT0065"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subissi</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Posthuma</surname><given-names>C. C.</given-names></name>, <name name-style="western"><surname>Collet</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Zevenhoven-Dobbe</surname><given-names>J. C.</given-names></name>, <name name-style="western"><surname>Gorbalenya</surname><given-names>A. E.</given-names></name>, <name name-style="western"><surname>Decroly</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Snijder</surname><given-names>E. J.</given-names></name>, <name name-style="western"><surname>Canard</surname><given-names>B.</given-names></name>, &#x00026; <name name-style="western"><surname>Imbert</surname><given-names>I.</given-names></name></person-group> (<year>2014</year>). <article-title>One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities</article-title>. <source><italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic></source>, (<issue>37</issue>), <fpage>E3900</fpage>&#x02013;<lpage>E3909</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1323705111</pub-id><pub-id pub-id-type="pmid">25197083</pub-id></mixed-citation></ref><ref id="CIT0066"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szajdek</surname><given-names>A.</given-names></name>, &#x00026; <name name-style="western"><surname>Borowska</surname><given-names>E.</given-names></name></person-group> (<year>2008</year>). <article-title>Bioactive compounds and health-promoting properties of berry fruits: A review</article-title>. <source><italic toggle="yes">Plant Foods for Human Nutrition (Dordrecht, Netherlands)</italic></source>, (<issue>4</issue>), <fpage>147</fpage>&#x02013;<lpage>156</lpage>. <pub-id pub-id-type="doi">10.1007/s11130-008-0097-5</pub-id></mixed-citation></ref><ref id="CIT0067"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trott</surname><given-names>O.</given-names></name>, &#x00026; <name name-style="western"><surname>Olson</surname><given-names>A. J.</given-names></name></person-group> (<year>2010</year>). <article-title>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title>. <source><italic toggle="yes">Journal of Computaional Chemistry</italic></source>, , <fpage>455</fpage>&#x02013;<lpage>461</lpage>.</mixed-citation></ref><ref id="CIT0068"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallace</surname><given-names>A. C.</given-names></name>, <name name-style="western"><surname>Laskowski</surname><given-names>R. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Thornton</surname><given-names>J. M.</given-names></name></person-group> (<year>1995</year>). <article-title>LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions</article-title>. <source><italic toggle="yes">Protein Engineering</italic></source>, (<issue>2</issue>), <fpage>127</fpage>&#x02013;<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1093/protein/8.2.127</pub-id><pub-id pub-id-type="pmid">7630882</pub-id></mixed-citation></ref><ref id="CIT0069"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Kollman</surname><given-names>P. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Case</surname><given-names>D. A.</given-names></name></person-group> (<year>2001</year>). <article-title>Antechamber: An accessory software package for molecular mechanical calculations</article-title>. <source><italic toggle="yes">Journal of the American Chemical Society</italic></source>, (<issue>17</issue>), <fpage>3986</fpage>&#x02013;<lpage>3994</lpage>. <pub-id pub-id-type="doi">10.1021/ja003164o</pub-id><pub-id pub-id-type="pmid">11457149</pub-id></mixed-citation></ref><ref id="CIT0070"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Kollman</surname><given-names>P. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Case</surname><given-names>D. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Automatic atom type and bond type perception in molecular mechanical calculations</article-title>. <source><italic toggle="yes">Journal of Molecular Graphics &#x00026; Modelling</italic></source>, (<issue>2</issue>), <fpage>247</fpage>&#x02013;<lpage>260</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmgm.2005.12.005</pub-id><pub-id pub-id-type="pmid">16458552</pub-id></mixed-citation></ref><ref id="CIT0071"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Wolf</surname><given-names>R. M.</given-names></name>, <name name-style="western"><surname>Caldwell</surname><given-names>J. W.</given-names></name>, <name name-style="western"><surname>Kollman</surname><given-names>P. A.</given-names></name>, &#x00026; <name name-style="western"><surname>Case</surname><given-names>D. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Development and testing of a general amber force field</article-title>. <source><italic toggle="yes">Journal of Computational Chemistry</italic></source>, (<issue>9</issue>), <fpage>1157</fpage>&#x02013;<lpage>1174</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.20035</pub-id><pub-id pub-id-type="pmid">15116359</pub-id></mixed-citation></ref><ref id="CIT0072"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.-M.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>Z.-G.</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Tao</surname><given-names>Z.-W.</given-names></name>, <name name-style="western"><surname>Tian</surname><given-names>J.-H.</given-names></name>, <name name-style="western"><surname>Pei</surname><given-names>Y.-Y.</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>M.-L.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.-L.</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>F.-H.</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Q.-M.</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>J.-J.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Holmes</surname><given-names>E. C.</given-names></name>, &#x00026; <name name-style="western"><surname>Zhang</surname><given-names>Y.-Z.</given-names></name></person-group> (<year>2020</year>). <article-title>A new coronavirus associated with human respiratory disease in China</article-title>. <source><italic toggle="yes">Nature</italic></source>, (<issue>7798</issue>), <fpage>265</fpage>&#x02013;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2008-3</pub-id></mixed-citation></ref><ref id="CIT0073"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name>, &#x00026; <name name-style="western"><surname>Gong</surname><given-names>P.</given-names></name></person-group> (<year>2018</year>). <article-title>Visualizing the nucleotide addition cycle of viral RNA-dependent RNA polymerase</article-title>. <source><italic toggle="yes">Viruses</italic></source>, (<issue>1</issue>), <fpage>24</fpage>
<pub-id pub-id-type="doi">10.3390/v10010024</pub-id></mixed-citation></ref><ref id="CIT0074"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name>, &#x00026; <name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name></person-group> (<year>2020</year>). <article-title>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</article-title>. <source><italic toggle="yes">Science (New York, N.Y.)</italic></source>, (<issue>6485</issue>), <fpage>1444</fpage>&#x02013;<lpage>1448</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb2762</pub-id></mixed-citation></ref><ref id="CIT0075"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Mao</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Luan</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>D.-D.</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>Y.-C.</given-names></name>, <name name-style="western"><surname>Tian</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>H.-W.</given-names></name>, <name name-style="western"><surname>Tao</surname><given-names>S.-C.</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name>, &#x02026; <name name-style="western"><surname>Xu</surname><given-names>H. E.</given-names></name></person-group> (<year>2020</year>). <article-title>Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir</article-title>. <source><italic toggle="yes">Science (New York, N.Y.)</italic></source>, (<issue>6498</issue>), <fpage>1499</fpage>&#x02013;<lpage>1504</lpage>. <pub-id pub-id-type="doi">10.1126/science.abc1560</pub-id></mixed-citation></ref><ref id="CIT0076"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>M.-S.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J. M.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Chin</surname><given-names>Y.-W.</given-names></name>, <name name-style="western"><surname>Jee</surname><given-names>J.-G.</given-names></name>, <name name-style="western"><surname>Keum</surname><given-names>Y.-S.</given-names></name>, &#x00026; <name name-style="western"><surname>Jeong</surname><given-names>Y.-J.</given-names></name></person-group> (<year>2012</year>). <article-title>Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13</article-title>. <source><italic toggle="yes">Bioorganic &#x00026; Medicinal Chemistry Letters</italic></source>, (<issue>12</issue>), <fpage>4049</fpage>&#x02013;<lpage>4054</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2012.04.081</pub-id><pub-id pub-id-type="pmid">22578462</pub-id></mixed-citation></ref><ref id="CIT0077"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhai</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Pang</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Bartlam</surname><given-names>M.</given-names></name>, &#x00026; <name name-style="western"><surname>Rao</surname><given-names>Z.</given-names></name></person-group> (<year>2005</year>). <article-title>Insights into SARS-CoV transcription and replication from the structure of the nsp7-nsp8 hexadecamer</article-title>. <source><italic toggle="yes">Nature Structural &#x00026; Molecular Biology</italic></source>, (<issue>11</issue>), <fpage>980</fpage>&#x02013;<lpage>986</lpage>. <pub-id pub-id-type="doi">10.1038/nsmb999</pub-id></mixed-citation></ref></ref-list></back></article>